[go: up one dir, main page]

EP1689370B1 - METHOD FOR THE PRODUCTION OF A SOLID, ORALLY APPLICABLE PHARMACEUTICAL COMPOSITION COMPRISING 5-Chlor-N ( { (5-2-oxo-3- [4- (3-oxo-4-morpholinyl)-phenyl]-1, 3- oxazolidin-5-yl}-methyl)-2-thiophencarboxamide - Google Patents

METHOD FOR THE PRODUCTION OF A SOLID, ORALLY APPLICABLE PHARMACEUTICAL COMPOSITION COMPRISING 5-Chlor-N ( { (5-2-oxo-3- [4- (3-oxo-4-morpholinyl)-phenyl]-1, 3- oxazolidin-5-yl}-methyl)-2-thiophencarboxamide Download PDF

Info

Publication number
EP1689370B1
EP1689370B1 EP04797879A EP04797879A EP1689370B1 EP 1689370 B1 EP1689370 B1 EP 1689370B1 EP 04797879 A EP04797879 A EP 04797879A EP 04797879 A EP04797879 A EP 04797879A EP 1689370 B1 EP1689370 B1 EP 1689370B1
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical composition
oxo
composition according
active compound
tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP04797879A
Other languages
German (de)
French (fr)
Other versions
EP1689370B2 (en
EP1689370A2 (en
Inventor
Klaus Benke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34609342&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1689370(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to PL04797879T priority Critical patent/PL1689370T5/en
Priority to SI200430675T priority patent/SI1689370T1/en
Priority to HRP20080150TT priority patent/HRP20080150T4/en
Priority to SI200430675A priority patent/SI1689370T2/en
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of EP1689370A2 publication Critical patent/EP1689370A2/en
Application granted granted Critical
Publication of EP1689370B1 publication Critical patent/EP1689370B1/en
Priority to CY20081100352T priority patent/CY1107369T1/en
Publication of EP1689370B2 publication Critical patent/EP1689370B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the present invention relates to a process for preparing a solid, orally applicable pharmaceutical composition containing 5-chloro-N - ( ⁇ (5 S) -2-oxa-3- [4- (3-oxo-4-morpholinyl) phenyl ] -1,3-oxazolidin-5-yl ⁇ -methyl) -2-thiophenecarboxamide in hydrophilized form and their use for the prophylaxis and / or treatment of diseases.
  • 5-chloro-N - ( ⁇ (5 S) -2-oxo-3- [4- (3-oxo-4-morpholinyl) phenyl] -1,3-oxazolidin-5-yl ⁇ methyl) -2 -thiopliencarboxamide (I) is a low molecular weight, orally applicable inhibitor of the blood coagulation factor Xa, which can be used for the prophylaxis and / or treatment of various thromboembolic disorders (see WO-A 01/47919 the disclosure of which is hereby incorporated by reference).
  • the active ingredient (I) has a relatively poor water solubility (about 7 mg / L). This may result in difficulties in oral bioavailability as well as increased biological variability of the absorption rate.
  • solutions of active ingredients are often used, which can be filled, for example, in soft gelatin capsules. Due to the poor solubility of the active ingredient (I) in the solvents suitable for this purpose, however, this option is not applicable in the present case, since in the necessary dose strength capsule sizes would result, which are no longer swallowable.
  • An alternative method is the amorphization of the active ingredient.
  • both the solution method turns out to be problematic because the active ingredient (I) is poorly soluble in pharmaceutically acceptable solvents such as ethanol or acetone.
  • An amorphization of the active ingredient via the melting method is unfavorable because of the high active ingredient melting point (about 230 ° C), since an undesirably high proportion of degradation components during manufacture.
  • the active ingredient (I) can either be presented as a solid in the premix (original) or it is suspended in the granulation liquid.
  • the active ingredient (I) is suspended in the granulation liquid in the wet granulation registered (suspension method).
  • the active ingredient (I) is used in crystalline form.
  • the crystalline active ingredient (I) is used in micronized form.
  • the active ingredient (I) preferably has one average particle size X 50 is less than 10 ⁇ m, in particular between 1 and 8 ⁇ m, and X 90 (90% proportion) is less than 20 ⁇ m, in particular less than 15 ⁇ m.
  • the granulation liquid used according to the invention contains a solvent, a hydrophilic binder and optionally a wetting agent.
  • the hydrophilic binder is dispersed in the granulation or preferably dissolved therein.
  • the solvent of the granulating liquid there may be used organic solvents such as ethanol or acetone, or water or mixtures thereof.
  • organic solvents such as ethanol or acetone, or water or mixtures thereof.
  • water is used as the solvent.
  • hydrophilic binder of the granulating liquid pharmaceutically suitable hydrophilic additives are used, preferably those which dissolve in the solvent of the granulating liquid.
  • Hydrophilic polymers such as, for example, hydroxypropylmethylcellulose (HPMC), carboxymethylcellulose (sodium and calcium salts), ethylcellulose, methylcellulose, hydroxyethylcellulose, ethylhydroxyethylcellulose, hydroxypropylcellulose (HPC), L-HPC (low substituted HPC), polyvinylpyrrolidone, polyvinyl alcohol, polymers of acrylic acid and their salts, vinylpyrrolidone-vinyl acetate copolymers (e.g., Kollidon ® VA64, BASF), gelatin, guar, partially hydrolyzed starch, alginates or xanthan used. Particularly preferred HPMC is used as a hydrophilic binder.
  • HPMC hydroxypropylmethylcellulose
  • HPC hydroxypropylcellulose
  • L-HPC low substituted HPC
  • polyvinylpyrrolidone polyvinyl alcohol
  • polymers of acrylic acid and their salts e.g., Kol
  • the hydrophilic binder may be present in a concentration of 1 to 15% (based on the total mass of the pharmaceutical composition), preferably from 1 to 8%.
  • wetting agents of the granulating liquid which may be present, pharmaceutically suitable wetting agents (surfactants) are used.
  • surfactants for example:
  • fatty alcohol sulfates such as sodium lauryl sulfate, sulfosuccinates such as sodium dioctyl sulfosuccinate, partial fatty acid esters of polyhydric alcohols such as glycerol monostearate, partial fatty acid esters of sorbitan such as sorbitan monolaurate, partial fatty acid esters of polyhydroxyethylene sorbitan such as polyethylene glycol sorbitan monolaurate, monostearate or monooleate, polyhydroxyethylene fatty alcohol ethers, polyhydroxyethylene fatty acid esters , ethylene oxide-propylene oxide block copolymers (Pluronic ®) and ethoxylated triglycerides.
  • sodium lauryl sulfate is used as wetting agent.
  • the wetting agent is used if necessary in a concentration of 0.1 to 5% (based on the total mass of the pharmaceutical composition), preferably from 0.1 to 2%.
  • disintegrators disintegrants
  • substances that affect the rate of release may be included. Examples include: hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose, ethylcellulose, carboxymethylcellulose, galactomannan, xanthan, glycerides, waxes, acrylic and / or methacrylic acid copolymers with trimethylammonium, acrylates Copolymers or methacrylic acid-acrylic acid methyl ester copolymers.
  • process step (a) The granules obtained in process step (a) are then converted into the pharmaceutical composition according to the invention in process step (b).
  • Process step (b) comprises, for example, tabletting, filling into capsules, preferably hard gelatin capsules, or filling as sachets, in each case by customary methods familiar to the person skilled in the art, if appropriate with the addition of further pharmaceutically suitable additives.
  • the present invention further provides a solid, orally administrable pharmaceutical composition
  • a solid, orally administrable pharmaceutical composition comprising 5-chloro- N - ( ⁇ (5 S) -2-oxo-3- [4- (3-oxo-4-morpholinyl) phenyl] - 1,3-oxazolidin-5-yl ⁇ -methyl) -2-thiophenecarboxamide (I) in hydrophilized form.
  • the solid, orally administrable pharmaceutical composition according to the invention comprises, by way of example and by way of preference, granules, granule-filled hard gelatin capsules or sachets and the active ingredient (I) tablets which release rapidly or modified (delayed). Preference is given to tablets, in particular the active ingredient (I) fast-release tablets.
  • fast-release tablets are in particular those which according to the USP release method with apparatus 2 (paddle), as described in the experimental section in chapter 5.2.2. described, have a Q value (30 minutes) of 75%.
  • the active ingredient (I) may be present in the pharmaceutical composition according to the invention in a concentration of 0.1 to 60%, preferably in a concentration of 1 to 40%, based on the total weight of the formulation.
  • the dose of the active ingredient (I) is preferably 1 to 100 mg.
  • the granules or tablets according to the invention are coated in a further step under customary conditions known to the person skilled in the art.
  • the coating is carried out with the addition of conventional, familiar to those skilled paint and film-forming agents such as hydroxypropylcellulose, hydroxypropylmethylcellulose, ethylcellulose, polyvinylpyrrolidone, vinylpyrrolidone-vinyl acetate copolymers (for example Kollidon ® VA64, BASF), shellac, acrylic and / or methacrylic acid copolymers with trimethylammonium , Copolymers of dimethylaminomethacrylic acid and neutral methacrylic acid esters, polymers of methacrylic acid or methacrylic acid esters, copolymers of ethyl acrylate and methyl acrylate, propylene glycol, polyethylene glycol, glycerol triacetate, triethyl citrate and / or color additives / pigments such as titanium dioxide, iron oxides,
  • the present invention further relates to the use of the pharmaceutical composition according to the invention for the prophylaxis and / or treatment of diseases, in particular thromboembolic diseases such as myocardial infarction, angina pectoris (including unstable angina), reocclusions and restenosis after angioplasty or aortocoronary bypass, stroke, transient ischemic Attacks, peripheral vascular disease, pulmonary embolism or deep venous thrombosis.
  • diseases in particular thromboembolic diseases such as myocardial infarction, angina pectoris (including unstable angina), reocclusions and restenosis after angioplasty or aortocoronary bypass, stroke, transient ischemic Attacks, peripheral vascular disease, pulmonary embolism or deep venous thrombosis.
  • Active ingredient (I) micronized 20.0 mg Microcrystalline cellulose 35.0 mg Lactose monohydrate 22.9 mg Croscarmellose (Ac-Di- Sol® , FMC) 3.0 mg Hydroxypropylmethylcellulose, 5 mPa.s 3.0 mg sodium lauryl sulfate 0.5 mg magnesium stearate 0.6 mg Hydroxypropyl methylcellulose, 15 mPa.s 1.5 mg Polyethylene glycol 3.350 0.5 mg Titanium dioxide 0.5 mg 87.5 mg
  • Hydroxypropylmethylcellulose (5 mPa.s) and sodium lauryl sulfate are dissolved in water.
  • the micronised active substance (I) is suspended in this solution.
  • the suspension thus prepared is sprayed as granulating liquid in the course of a fluidized bed granulation onto the initial charge of microcrystalline cellulose, lactose monohydrate and croscarmellose. After drying and sieving (0.8 mm mesh size) of the resulting granules, magnesium stearate is added and mixed.
  • the press-ready mixture thus obtained is compressed into tablets of 6 mm diameter and a breaking strength of 50-100 N.
  • the subsequent coating of the tablets is carried out with titanium dioxide, which is suspended in an aqueous solution of hydroxypropylmethylcellulose (15 mPa.s) and polyethylene glycol.
  • Active ingredient (I) micronized 5.0 mg Microcrystalline cellulose 40.0 mg Lactose monohydrate 33.9 mg Croscarmellose (Ac-Di- Sol® , FMC) 3.0 mg Hydroxypropylmethylcellulose, 3 mPa ⁇ s 2.0 mg sodium lauryl sulfate 0.5 mg magnesium stearate 0.6 mg Hydroxypropyl methylcellulose, 15 mPa.s 1.5 mg Polyethylene glycol 400 0.5 mg Iron oxide yellow 0.1 mg Titanium dioxide 0.4 mg 87.5 mg
  • microcrystalline cellulose, lactose monohydrate and croscarmellose are mixed (granule template). Hydroxypropylmethyl cellulose (3 mPa.s) and sodium lauryl sulfate are dissolved in water. In this solution, the micronized drug (I) is suspended. The suspension prepared in this way is added to the granule template as granulation liquid and uniformly mixed with the granule master by means of the rapidly rotating stirrer. After mixing, the moist granules are sieved (4 mm mesh size) and dried in the fluidized bed. After sieving the dried granules (0.8 mm mesh size), magnesium stearate is added and mixed.
  • the press-ready mixture thus obtained is compressed into tablets of 6 mm diameter and a breaking strength of 50-100 N.
  • the subsequent coating of the tablets is carried out with titanium dioxide and iron oxide yellow, wherein the pigments are previously suspended in an aqueous solution of hydroxypropyl methylcellulose (15 mPa ⁇ s) and polyethylene glycol.
  • Active ingredient (I) micronized 50.0 mg mannitol 662.0 mg Croscarmellose (Ac-Di- Sol® , FMC) 15.0 mg Hydroxypropylmethylcellulose, 5 mPas 15.0 mg sodium lauryl sulfate 1.0 mg Colloidal anhydrous silica (Aerosil ® 200, Degussa) 2.0 mg Strawberry flavor, spray dried 5.0 mg 750.0 mg
  • hydroxypropylmethylcellulose (5 mPa.s) and sodium lauryl sulfate were dissolved in water.
  • the micronized drug (I) is suspended.
  • the suspension thus prepared is sprayed as a granulation liquid in a fluidized bed on the template of mannitol and croscarmellose After drying and sieving (0.8 mm mesh width) the resulting granules are added and mixed colloidal silicon dioxide (Aerosil ®), and strawberry flavor.
  • the resulting mixture is filled into sachet bags of 750 mg each using a sachet filling machine.
  • Active ingredient (I) micronized 20.0 mg Microcrystalline cellulose 30.0 mg Lactose monohydrate 79.5 mg corn starch 25.0 mg Hydroxypropylmethylcellulose, 5 mPas 4.5 mg sodium lauryl sulfate 0.5 mg Colloidal anhydrous silica (Aerosil ® 200, Degussa) 0.5 mg 160.0 mg
  • Hydroxypropylmethylcellulose (5 mPas) and sodium lauryl sulfate are dissolved in water.
  • the micronized active substance (I) is suspended in this solution.
  • the suspension thus prepared is sprayed as a granulating liquid in a fluidized bed granulation on the template of microcrystalline cellulose, lactose monohydrate and corn starch. After drying and sieving (0.8 mm mesh width) the resulting granules is highly disperse silica (Aerosil ®) was added and mixed. The resulting mixture is filled to 160 mg each in capsule size 2 hard gelatin capsules
  • unpainted tablets with 10 mg active ingredient content (I) of the following composition are prepared (in mg / tablet): Active ingredient (I), micronized 10.0 mg Microcrystalline cellulose 40.0 mg Lactose monohydrate 27.9 mg Croscarmellose (Ac-Di- Sol® , FMC) 3.0 mg Hydroxypropylmethylcellulose, 5 mPas 3.0 mg sodium lauryl sulfate 0.5 mg magnesium stearate 0.6 mg 85.0 mg
  • Tablet A prepared by direct tableting without granulation
  • Tablet B prepared by the fluidized bed granulation / suspension method described under 1.2
  • the mixture for tablet A and the granules for tablet B are each pressed into tablets with a diameter of 6 mm and a breaking strength of about 70-80 N.
  • Tablet A about 1.5 minutes
  • Tablet B about 6.5 minutes
  • Table 1 below shows the quantities of active substance released based on the declared total content of the tablets: ⁇ b> ⁇ i> Table 1: in vitro release ⁇ / i> ⁇ /b> 15 minutes 30 min 45 min 60 min Tablet A 87% 92% 93% 94% Tablet B 94% 95% 96% 96% (USP paddle, 900 ml acetate buffer pH 4.5 + 0.5% sodium lauryl sulfate, 75 rpm)
  • tablet B Despite slower disintegration (see 5.2.1) and very similar in vitro release (see 5.2.2) of tablet B compared to tablet A, tablet B has distinct advantages in absorption and thus increased bioavailability by about 35% , At the same time, there is a significant decrease in variability.
  • the only difference between tablet A and tablet B is the hydrophilization of the active ingredient (I) in tablet B by means of the wet granulation suspension method.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention relates to a method for producing a solid, orally applicable pharmaceutical composition containing 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophen carboxamide in a hydrophilized form, and the use thereof for preventing and/or treating diseases.

Description

Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung, enthaltend 5-Chlor-N-({(5S)-2-oxa-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid in hydrophilisierter Form sowie ihre Verwendung zur Prophylaxe und/oder Behandlung von Erkrankungen.The present invention relates to a process for preparing a solid, orally applicable pharmaceutical composition containing 5-chloro-N - ({(5 S) -2-oxa-3- [4- (3-oxo-4-morpholinyl) phenyl ] -1,3-oxazolidin-5-yl} -methyl) -2-thiophenecarboxamide in hydrophilized form and their use for the prophylaxis and / or treatment of diseases.

5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiopliencarboxamid (I) ist ein niedermolekularer, oral applizierbarer Inhibitor des Blutgerinnungsfaktors Xa, der zur Prophylaxe und/oder Behandlung verschiedener thromboembolischer Erlaankungen eingesetzt werden kann (siehe hierzu WO-A 01/47919 , deren Offenbarung hiermit durch Bezugnahme eingeschlossen ist). Wenn im folgenden vom Wirkstoff (I) die Rede ist, so sind dabei alle Modifikationen von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid (I) sowie die jeweiligen Hydrate mit umfasst. 5-chloro-N - ({(5 S) -2-oxo-3- [4- (3-oxo-4-morpholinyl) phenyl] -1,3-oxazolidin-5-yl} methyl) -2 -thiopliencarboxamide (I) is a low molecular weight, orally applicable inhibitor of the blood coagulation factor Xa, which can be used for the prophylaxis and / or treatment of various thromboembolic disorders (see WO-A 01/47919 the disclosure of which is hereby incorporated by reference). When the following is the active ingredient (I), all modifications of 5-chloro- N - ({(5 S ) -2-oxo-3- [4- (3-oxo-4-morpholinyl) - phenyl] -1,3-oxazolidin-5-yl} -methyl) -2-thiophenecarboxamide (I) and the respective hydrates.

Der Wirkstoff (I) weist eine relativ schlechte Wasserlöslichkeit auf (ca. 7 mg/L). Dadurch können sich Schwierigkeiten bei der oralen Bioverfügbarkeit sowie eine erhöhte biologische Variabilität der Absorptionsrate ergeben.The active ingredient (I) has a relatively poor water solubility (about 7 mg / L). This may result in difficulties in oral bioavailability as well as increased biological variability of the absorption rate.

Zur Erhöhung der oralen Bioverfügbarkeit sind in der Vergangenheit verschiedene Konzepte beschrieben worden:To increase oral bioavailability, various concepts have been described in the past:

So werden häufig Lösungen von Wirkstoffen angewendet, die beispielsweise in Weichgelatinekapseln abgefüllt werden können. Aufgrund der schlechten Löslichkeit des Wirkstoffes (I) in den für diesen Zweck geeigneten Lösungsmitteln ist diese Option im vorliegenden Fall aber nicht anwendbar, da in der notwendigen Dosisstärke Kapselgrößen resultieren würden, die nicht mehr schluckbar sind.Thus, solutions of active ingredients are often used, which can be filled, for example, in soft gelatin capsules. Due to the poor solubility of the active ingredient (I) in the solvents suitable for this purpose, however, this option is not applicable in the present case, since in the necessary dose strength capsule sizes would result, which are no longer swallowable.

Ein alternatives Verfahren stellt die Amorphisierung des Wirkstoffes dar. Hierbei erweist sich sowohl die Lösungsmethode als problematisch, da der Wirkstoff (I) auch in pharmazeutisch akzeptablen Lösemittel wie Ethanol oder Aceton schlecht löslich ist. Auch eine Amorphisierung des Wirkstoffes über die Schmelzmethode ist wegen des hohen Wirkstoff-Schmelzpunktes (ca. 230°C) ungünstig, da ein unerwünscht hoher Anteil von Abbaukomponenten während der Herstellung entsteht.An alternative method is the amorphization of the active ingredient. In this case, both the solution method turns out to be problematic because the active ingredient (I) is poorly soluble in pharmaceutically acceptable solvents such as ethanol or acetone. An amorphization of the active ingredient via the melting method is unfavorable because of the high active ingredient melting point (about 230 ° C), since an undesirably high proportion of degradation components during manufacture.

Weiterhin ist ein Verfahren zur Hydrophilisierung von hydrophoben Wirkstoffen am Beispiel von Hexobarbital und Phenytoin beschrieben worden ( Lerk, Lagas, Fell, Nauta, Journal of Pharmaceutical Sciences Vol. 67, No. 7, July 1978, 935 - 939: "Effect of Hydrophilization of Hydrophobic Drugs on Release Rate from Capsules "; Lerk, Lagas, Lie-A-Huen, Broersma, Zuurman, Journal of Pharmaceutical Sciences Vol. 68, No. 5, May 1979, 6,34-638: "In Vitro and In Vivo Availability of Hydrophilized Phenytoin from Capsules "). Die WirkstofReilchen werden hierbei in einem Mischer unter weitgehender Vermeidung eines Agglomerationsschrittes mit einer Methyl- bzw. Hydroxyethylcellulose-Lösung vermischt und dann getrocknet. Der so erhaltene Wirkstoff wird anschließend ohne weitere Behandlung in Hartgelatinekapseln abgefüllt.Furthermore, a method for the hydrophilization of hydrophobic drugs has been described using the example of hexobarbital and phenytoin ( Lerk, Lagas, Fell, Nauta, Journal of Pharmaceutical Sciences Vol. 67, no. 7, July 1978, 935-939: "Effect of Hydrophilization of Hydrophobic Drugs on Release Rate from Capsules "; Lerk, Lagas, Lie-A-Huen, Broersma, Zuurman, Journal of Pharmaceutical Sciences Vol. 5, May 1979, 6, 34-638: "In Vitro and In Vivo Availability of Hydrophilized Phenytoin from Capsules The active substance particles are in this case mixed with a methyl or hydroxyethyl cellulose solution in a mixer while largely avoiding an agglomeration step and then dried The active ingredient thus obtained is subsequently filled into hard gelatine capsules without further treatment.

Überraschenderweise wurde nun gefunden, dass eine spezielle Behandlung der Oberfläche des Wirkstoffes (I) im Rahmen der Feuchtgranulation ein verbessertes Absorptionsverhalten bewirkt. Die Verwendung des Wirkstoffes (I) in hydrophilisierter Form bei der Herstellung von festen, oral applizierbaren pharmazeutischen Zusammensetzungen führt zu einer signifikanten Erhöhung der Bioverfügbarkeit der so erhaltenen Formulierung.Surprisingly, it has now been found that a special treatment of the surface of the active ingredient (I) in the context of wet granulation causes an improved absorption behavior. The use of the active ingredient (I) in hydrophilized form in the preparation of solid, orally administrable pharmaceutical compositions leads to a significant increase in the bioavailability of the formulation thus obtained.

Gegenstand der vorliegenden Erfindung ist ein Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung enthaltend 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid in hydrophilisierter Form, wobei

  1. (a) zunächst ein den Wirkstoff (I) in hydrophilisierter Form enthaltendes Granulat durch Feuchtgranulation hergestellt wird
  2. (b) und das Granulat dann, gegebenenfalls unter Zusatz pharmazeutisch geeigneter Zusatzstoffe, in die pharmazeutische Zusammensetzung überführt wird.
The present invention is a process for preparing a solid, orally applicable pharmaceutical composition containing 5-chloro-N - ({(5 S) -2-oxo-3- [4- (3-oxo-4-morpholinyl) phenyl ] -1,3-oxazolidin-5-yl} -methyl) -2-thiophenecarboxamide in hydrophilized form, wherein
  1. (A) first a granule containing the active ingredient (I) in hydrophilized form is produced by wet granulation
  2. (B) and then the granules, optionally with the addition of pharmaceutically suitable additives, in the pharmaceutical composition is transferred.

Die Feuchtgranulation im Verfahrensschritt (a) kann in einem Mischer (= Mischergranulation) oder in einer Wirbelschicht (= Wirbelschichtgranulation) erfolgen, bevorzugt ist die Wirbelschichtgranulation.The wet granulation in process step (a) can be carried out in a mixer (= mixer granulation) or in a fluidized bed (= fluidized bed granulation), fluid bed granulation is preferred.

Bei der Feuchtgranulation kann der Wirkstoff (I) entweder als Feststoff in der Vormischung (Vorlage) vorgelegt werden oder er wird in der Granulierflüssigkeit suspendiert. Bevorzugt wird der Wirkstoff (I) in der Granulierflüssigkeit suspendiert in die Feuchtgranulation eingetragen (Suspensionsverfahren).In wet granulation, the active ingredient (I) can either be presented as a solid in the premix (original) or it is suspended in the granulation liquid. Preferably, the active ingredient (I) is suspended in the granulation liquid in the wet granulation registered (suspension method).

In einer bevorzugten Ausführungsform der vorliegenden Erfindung wird der Wirkstoff (I) in kristalliner Form eingesetzt.In a preferred embodiment of the present invention, the active ingredient (I) is used in crystalline form.

In einer besonders bevorzugten Ausführungsform der vorliegenden Erfindung wird der kristalline Wirkstoff (I) in mikronisierter Form eingesetzt. Der Wirkstoff (I) besitzt dabei vorzugsweise eine mittlere Partikelgröße X50 kleiner 10 µm, insbesondere zwischen 1 und 8 µm sowie X90 (90 %-Anteil) kleiner 20 µm, insbesondere kleiner 15 µm.In a particularly preferred embodiment of the present invention, the crystalline active ingredient (I) is used in micronized form. The active ingredient (I) preferably has one average particle size X 50 is less than 10 μm, in particular between 1 and 8 μm, and X 90 (90% proportion) is less than 20 μm, in particular less than 15 μm.

Die erfindungsgemäß verwendete Granulierflüssigkeit enthält ein Lösungsmittel, ein hydrophiles Bindemittel und gegebenenfalls ein Netzmittel. Das hydrophile Bindemittel ist dabei in der Granulierflüssigkeit dispergiert oder vorzugsweise darin gelöst.The granulation liquid used according to the invention contains a solvent, a hydrophilic binder and optionally a wetting agent. The hydrophilic binder is dispersed in the granulation or preferably dissolved therein.

Als Lösungsmittel der Granulierflüssigkeit können organische Lösungsmittel, wie beispielsweise Ethanol oder Aceton, oder Wasser oder Gemische davon verwendet werden. Bevorzugt wird Wasser als Lösungsmittel verwendet.As the solvent of the granulating liquid, there may be used organic solvents such as ethanol or acetone, or water or mixtures thereof. Preferably, water is used as the solvent.

Als hydrophile Bindemittel der Granulierflüssigkeit werden pharmazeutisch geeignete hydrophile Zusatzstoffe eingesetzt, vorzugsweise solche, die sich im Lösungsmittel der Granulierflüssigkeit lösen.As the hydrophilic binder of the granulating liquid, pharmaceutically suitable hydrophilic additives are used, preferably those which dissolve in the solvent of the granulating liquid.

Vorzugsweise werden dabei hydrophile Polymere wie beispielsweise Hydroxypropylmethylcellulose (HPMC), Carboxymethylcellulose (Natrium- und Calciumsalze), Ethylcellulose, Methylcellulose, Hydroxyethylcellulose, Ethylhydroxyethylcellulose, Hydroxypropylcellulose (HPC), L-HPC (niedrigsubstituierte HPC), Polyvinylpyrrolidon, Polyvinylalkohol, Polymere der Acrylsäure und deren Salze, Vinylpyrrolidon-Vinylacetat-Copolymere (beispielsweise Kollidon® VA64, BASF), Gelatine, Guargummi, partiell hydrolisierte Stärke, Alginate oder Xanthan eingesetzt. Besonders bevorzugt wird HPMC als hydrophiles Bindemittel eingesetzt.Hydrophilic polymers such as, for example, hydroxypropylmethylcellulose (HPMC), carboxymethylcellulose (sodium and calcium salts), ethylcellulose, methylcellulose, hydroxyethylcellulose, ethylhydroxyethylcellulose, hydroxypropylcellulose (HPC), L-HPC (low substituted HPC), polyvinylpyrrolidone, polyvinyl alcohol, polymers of acrylic acid and their salts, vinylpyrrolidone-vinyl acetate copolymers (e.g., Kollidon ® VA64, BASF), gelatin, guar, partially hydrolyzed starch, alginates or xanthan used. Particularly preferred HPMC is used as a hydrophilic binder.

Das hydrophile Bindemittel kann dabei in einer Konzentration von 1 bis 15 % (bezogen auf die Gesamtmasse der pharmazeutischen Zusammensetzung), vorzugsweise von 1 bis 8 % enthalten sein.The hydrophilic binder may be present in a concentration of 1 to 15% (based on the total mass of the pharmaceutical composition), preferably from 1 to 8%.

Als gegebenenfalls vorhandene Netzmittel der Granulierflüssigkeit werden pharmazeutisch geeignete Netzmittel (Tenside) eingesetzt. Beispielsweise seien genannt:As wetting agents of the granulating liquid which may be present, pharmaceutically suitable wetting agents (surfactants) are used. For example:

Natriumsalze von Fettalkoholsulfaten wie Natriumlaurylsulfat, Sulfosuccinate wie Natriumdioctylsulfosuccinat, partielle Fettsäureester mehrwertiger Alkohole wie Glycerinmonostearat, partielle Fettsäureester des Sorbitans wie Sorbitanmonolaurat, partielle Fettsäureester des Polyhydroxyethylensorbitans wie Polyethylenglycol-Sorbitan-monolaurat, -monostearat oder -monooleat, Polyhydroxyethylen-Fett-alkoholether, Polyhydroxyethylen-Fettsäureester, Ethylenoxid-Propylenoxid-Blockcopolymere (Pluronic®) oder ethoxylierte Triglyceride. Bevorzugt wird Natriumlaurylsulfat als Netzmittel eingesetzt.Sodium salts of fatty alcohol sulfates such as sodium lauryl sulfate, sulfosuccinates such as sodium dioctyl sulfosuccinate, partial fatty acid esters of polyhydric alcohols such as glycerol monostearate, partial fatty acid esters of sorbitan such as sorbitan monolaurate, partial fatty acid esters of polyhydroxyethylene sorbitan such as polyethylene glycol sorbitan monolaurate, monostearate or monooleate, polyhydroxyethylene fatty alcohol ethers, polyhydroxyethylene fatty acid esters , ethylene oxide-propylene oxide block copolymers (Pluronic ®) and ethoxylated triglycerides. Preferably, sodium lauryl sulfate is used as wetting agent.

Das Netzmittel wird bei Bedarf in einer Konzentration von 0.1 bis 5 % (bezogen auf die Gesamtmasse der pharmazeutischen Zusammensetzung), vorzugsweise von 0.1 bis 2 % eingesetzt.The wetting agent is used if necessary in a concentration of 0.1 to 5% (based on the total mass of the pharmaceutical composition), preferably from 0.1 to 2%.

In der Vormischung (Vorlage) der Feuchtgranulation sind weitere pharmazeutisch geeignete Zusatzstoffe enthalten. Beispielsweise seien genannt:

  • Füllstoffe und Trockenbindemittel wie Cellulosepulver, mikrokristalline Cellulose, verkieselte mikrokristalline Cellulose, Dicalciumphosphat, Tricalciumphosphat, Magnesiumtrisilikat, Mannitol, Maltitol, Sorbitol, Xylitol, Laktose (wasserfrei oder als Hydrat, beispielsweise Monohydrat), Dextrose, Maltose, Saccharose, Glucose, Fructose oder Maltodextrine
  • Zerfallsförderer (Sprengmittel) wie Carboxymethylcellulose, Croscarmellose (quervernetzte Carboxymethylcellulose), Crospovidone (quervernetztes Polyvinylpyrrolidon), L-HPC (niedrigsubstituierte Hydroxypropylcellulose), Natriumcarboxymethylstärke, Natriumglykolat der Kartoffelstärke, partiell hydrolisierte Stärke, Weizenstärke, Maisstärke, Reisstärke oder Kartoffelstärke
In the masterbatch (template) of the wet granulation further pharmaceutically suitable additives are included. For example:
  • Fillers and dry binders such as cellulose powder, microcrystalline cellulose, silicified microcrystalline cellulose, dicalcium phosphate, tricalcium phosphate, magnesium trisilicate, mannitol, maltitol, sorbitol, xylitol, lactose (anhydrous or as hydrate, for example monohydrate), dextrose, maltose, sucrose, glucose, fructose or maltodextrins
  • Disintegrants (disintegrants) such as carboxymethylcellulose, croscarmellose (cross-linked carboxymethylcellulose), crospovidone (cross-linked polyvinylpyrrolidone), L-HPC (low substituted hydroxypropylcellulose), sodium carboxymethylstarch, potato starch sodium glycolate, partially hydrolyzed starch, wheat starch, corn starch, rice starch or potato starch

Im Fall von Tablettenformulierungen mit modifizierter (verzögerter) Wirkstofffreisetzung können statt der Zerfallsförderer (Sprengmittel) Stoffe enthalten sein, die die Freisetzungsrate beeinflussen. Beispielsweise seien genannt: Hydroxypropylcellulose, Hydroxypropylmethylcellulose, Methylcellulose, Ethylcellulose, Carboxymethylcellulose, Galaktomannan, Xanthan, Glyceride, Wachse, Acryl- und/oder Methacrylsäureester-Copolymerisate mit Trimethylammoniummethylacrylat, Copolymerisate von Dimethylaminomethacrylsäure und neutralen Methacrylsäureestern, Polymerisate von Methacrylsäure oder Methacrylsäureestern, Acrylsäureethylester-Methacrylsäuremethylester-Copolymerisate oder Methacrylsäure-Acrylsäuremethylester-Copolymerisate.In the case of modified (sustained release) tablet formulations, instead of the disintegrators (disintegrants), substances that affect the rate of release may be included. Examples include: hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose, ethylcellulose, carboxymethylcellulose, galactomannan, xanthan, glycerides, waxes, acrylic and / or methacrylic acid copolymers with trimethylammonium, acrylates Copolymers or methacrylic acid-acrylic acid methyl ester copolymers.

Das im Verfahrensschritt (a) erhaltene Granulat wird anschließend im Verfahrensschritt (b) in die erfindungsgemäße pharmazeutische Zusammensetzung überführt.The granules obtained in process step (a) are then converted into the pharmaceutical composition according to the invention in process step (b).

Der Verfahrensschritt (b) umfasst beispielsweise Tablettieren, Abfüllen in Kapseln, vorzugsweise Hartgelatinekapseln, oder Abfüllen als Sachets, jeweils nach üblichen, dem Fachmann geläufigen Methoden, gegebenenfalls unter Zusatz weiterer pharmazeutisch geeigneter Zusatzstoffe.Process step (b) comprises, for example, tabletting, filling into capsules, preferably hard gelatin capsules, or filling as sachets, in each case by customary methods familiar to the person skilled in the art, if appropriate with the addition of further pharmaceutically suitable additives.

Als pharmazeutisch geeignete Zusatzstoffe seien beispielsweise genannt:

  • Schmier-, Gleit-, Fließregulienmgsmittel wie Fumarsäure, Staearinsäure, Magnesiumstearat, Calciumstearat, Natriumstearylfumarat, höhermolekulare Fettalkohole, Polyethylenglykole, Stärke (Weizen-, Reis,- Mais- oder Kartoffelstärke), Talkum, hochdisperses (kolloidales) Siliciumdioxid, Magnesiumoxid, Magnesiumcarbonat oder Calciumsilikat
  • Zerfallsförderer (Sprengmittel) wie Carboxymethylcellulose, Croscarmellose (quervernetzte Carboxymethylcellulose), Crospovidone (quervernetztes Polyvinylpyrrolidon), L-HPC (niedrigsubstituierte Hydroxypropylcellulose), Natriumcarboxymethylstärke, partiell hydrolisierte Stärke, Weizenstärke, Maisstärke, Reisstärke oder Kartoffelstärke
As pharmaceutically suitable additives may be mentioned, for example:
  • Lubricants, lubricants, flow regulators such as fumaric acid, stearic acid, magnesium stearate, calcium stearate, sodium stearyl fumarate, higher molecular weight fatty alcohols, polyethylene glycols, Starch (wheat, rice, maize or potato starch), talc, fumed (colloidal) silica, magnesium oxide, magnesium carbonate or calcium silicate
  • Disintegrants (disintegrants) such as carboxymethylcellulose, croscarmellose (cross-linked carboxymethylcellulose), crospovidone (cross-linked polyvinylpyrrolidone), L-HPC (low substituted hydroxypropylcellulose), sodium carboxymethylstarch, partially hydrolyzed starch, wheat starch, corn starch, rice starch or potato starch

Weiterer Gegenstand der vorliegenden Erfindung ist eine feste, oral applizierbare pharmazeutische Zusammensetzung, enthaltend 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid (I) in hydrophilisierter Form.The present invention further provides a solid, orally administrable pharmaceutical composition comprising 5-chloro- N - ({(5 S) -2-oxo-3- [4- (3-oxo-4-morpholinyl) phenyl] - 1,3-oxazolidin-5-yl} -methyl) -2-thiophenecarboxamide (I) in hydrophilized form.

Die erfindungsgemäße feste, oral applizierbare pharmazeutische Zusammensetzung umfasst beispielhaft und vorzugsweise Granulate, mit Granulat gefüllte Hartgelatinekapseln oder Sachets sowie den Wirkstoff (I) schnell oder modifiziert (verzögert) freisetzende Tabletten. Bevorzugt sind Tabletten, insbesondere den Wirkstoff (I) schnell freisetzende Tabletten. Im Rahmen der vorliegenden Erfindung sind schnellfreisetzende Tabletten insbesondere solche, die gemäß USP-Freisetzungsmethode mit Apparatur 2 (Paddle), wie im experimentellen Teil in Kapitel 5.2.2. beschrieben, einen Q-Wert (30 Minuten) von 75 % besitzen.The solid, orally administrable pharmaceutical composition according to the invention comprises, by way of example and by way of preference, granules, granule-filled hard gelatin capsules or sachets and the active ingredient (I) tablets which release rapidly or modified (delayed). Preference is given to tablets, in particular the active ingredient (I) fast-release tablets. In the context of the present invention, fast-release tablets are in particular those which according to the USP release method with apparatus 2 (paddle), as described in the experimental section in chapter 5.2.2. described, have a Q value (30 minutes) of 75%.

Der Wirkstoff (I) kann in der erfindungsgemäßen pharmazeutischen Zusammensetzung in einer Konzentration von 0,1 bis 60 %, vorzugsweise in einer Konzentration von 1 bis 40 %, bezogen auf die Gesamtmasse der Formulierung, vorliegen. Hierbei beträgt die Dosis des Wirkstoffes (I) vorzugsweise 1 bis 100 mg.The active ingredient (I) may be present in the pharmaceutical composition according to the invention in a concentration of 0.1 to 60%, preferably in a concentration of 1 to 40%, based on the total weight of the formulation. Here, the dose of the active ingredient (I) is preferably 1 to 100 mg.

Gegebenenfalls werden die erfindungsgemäßen Granulate oder Tabletten in einem weiteren Schritt unter üblichen, dem Fachmann geläufigen Bedingungen lackiert. Die Lackierung erfolgt unter Zusatz von üblichen, dem Fachmann geläufigen Lackier- und Filmbildemitteln wie Hydroxypropylcellulose, Hydroxypropylmethylcellulose, Ethylcellulose, Polyvinylpyrrolidon, Vinylpyrrolidon-Vinylacetat-Copolymere (beispielsweise Kollidon® VA64, BASF), Schellack, Acryl- und/oder Methacrylsäureester-Copolymerisate mit Trimethylammoniummethylacrylat, Copolymerisate von Dimethylaminomethacrylsäure und neutralen Methacrylsäureestern, Polymerisate von Methacrylsäure oder Methacrylsäureestern, Acrylsäureethylester-Methacrylsäuremethylester-Copolymerisate, Methacrylsäure-Acrylsäuremethylester-Copolymerisate, Propylenglykol, Polyethylenglykol, Glycerintriacetat, Triethylcitrat und/oder Farbzusätzen/Pigmenten wie beispielsweise Titandioxid, Eisenoxide, Indigotin oder geeigneter Farblacke.If appropriate, the granules or tablets according to the invention are coated in a further step under customary conditions known to the person skilled in the art. The coating is carried out with the addition of conventional, familiar to those skilled paint and film-forming agents such as hydroxypropylcellulose, hydroxypropylmethylcellulose, ethylcellulose, polyvinylpyrrolidone, vinylpyrrolidone-vinyl acetate copolymers (for example Kollidon ® VA64, BASF), shellac, acrylic and / or methacrylic acid copolymers with trimethylammonium , Copolymers of dimethylaminomethacrylic acid and neutral methacrylic acid esters, polymers of methacrylic acid or methacrylic acid esters, copolymers of ethyl acrylate and methyl acrylate, propylene glycol, polyethylene glycol, glycerol triacetate, triethyl citrate and / or color additives / pigments such as titanium dioxide, iron oxides, indigotin or suitable color lakes.

Weiterer Gegenstand der vorliegenden Erfindung ist die Verwendung der erfindungsgemäßen pharmazeutischen Zusammensetzung zur Prophylaxe und/oder Behandlung von Erkrankungen, insbesondere von thromboembolischen Erkrankungen wie Herzinfarkt, Angina Pectoris (eingeschlossen instabile Angina), Reokklusionen und Restenosen nach einer Angioplastie oder aortokoronarem Bypass, Hirnschlag, transitorische ischämische Attacken, periphere arterielle Verschlusskrankheiten, Lungenembolien oder tiefen venösen Thrombosen.The present invention further relates to the use of the pharmaceutical composition according to the invention for the prophylaxis and / or treatment of diseases, in particular thromboembolic diseases such as myocardial infarction, angina pectoris (including unstable angina), reocclusions and restenosis after angioplasty or aortocoronary bypass, stroke, transient ischemic Attacks, peripheral vascular disease, pulmonary embolism or deep venous thrombosis.

Die Erfindung wird nachstehend durch bevorzugte Ausführungsbeispiele näher erläutert. Soweit nicht anders angegeben, beziehen sich nachstehend alle Mengenangaben auf Gewichtsprozente.The invention will be explained in more detail below by preferred embodiments. Unless otherwise indicated, all quantities below refer to percentages by weight.

Experimenteller TeilExperimental part 1. Tablettenherstellung mit Granulaten enthaltend den Wirkstoff (I) in hydrophilisierter Form / Wirbelschichtgranulationseverfahren 1. tablet production with granules containing the active ingredient (I) in hydrophilized form / fluidized bed granulation 1.1 Tablettenzusammensetzung (in mg/Tablette)1.1 tablet composition (in mg / tablet)

Wirkstoff (I), mikronisiertActive ingredient (I), micronized 20.0 mg20.0 mg Mikrokristalline CelluloseMicrocrystalline cellulose 35.0 mg35.0 mg Laktose MonohydratLactose monohydrate 22.9 mg22.9 mg Croscarmellose (Ac-Di-Sol®, FMC)Croscarmellose (Ac-Di- Sol® , FMC) 3.0 mg3.0 mg Hydroxypropylmethylcellulose, 5 mPa·sHydroxypropylmethylcellulose, 5 mPa.s 3.0 mg3.0 mg Natriumlaurylsulfatsodium lauryl sulfate 0.5 mg0.5 mg Magnesiumstearatmagnesium stearate 0.6 mg0.6 mg Hydroxypropylmethylcellulose, 15 mPa·sHydroxypropyl methylcellulose, 15 mPa.s 1.5 mg1.5 mg Polyethylenglykol 3.350Polyethylene glycol 3.350 0.5 mg0.5 mg TitandioxidTitanium dioxide 0.5 mg0.5 mg 87.5 mg87.5 mg

1.2 Herstellung1.2 Production

Hydroxypropylmethylcellulose (5 mPa·s) und Natriumlaurylsulfat werden in Wasser gelöst In diese Lösung wird der mikronisierte Wirkstoff (I) suspendiert. Die so hergestellte Suspension wird als Granulierflüssigkeit im Rahmen einer Wirbelschichtgranulation auf die Vorlage aus mikrokristalliner Cellulose, Laktose Monohydrat und Croscarmellose aufgesprüht. Nach Trocknung und Siebung (0.8 mm Maschenweite) des entstandenen Granulates wird Magnesiumstearat zugegeben und gemischt. Die so erhaltene pressfertige Mischung wird zu Tabletten mit 6 mm Durchmesser und einer Bruchfestigkeit von 50 - 100 N verpresst. Die anschließende Lackierung der Tabletten erfolgt mit Titandioxid, das in einer wässrigen Lösung aus Hydroxypropylmethylcellulose (15 mPa·s) und Polyethylenglykol suspendiert ist.Hydroxypropylmethylcellulose (5 mPa.s) and sodium lauryl sulfate are dissolved in water. The micronised active substance (I) is suspended in this solution. The suspension thus prepared is sprayed as granulating liquid in the course of a fluidized bed granulation onto the initial charge of microcrystalline cellulose, lactose monohydrate and croscarmellose. After drying and sieving (0.8 mm mesh size) of the resulting granules, magnesium stearate is added and mixed. The press-ready mixture thus obtained is compressed into tablets of 6 mm diameter and a breaking strength of 50-100 N. The subsequent coating of the tablets is carried out with titanium dioxide, which is suspended in an aqueous solution of hydroxypropylmethylcellulose (15 mPa.s) and polyethylene glycol.

2. Tablettenherstellung mit Granulaten enthaltend den Wirkstoff (I) in hydrophilisierter Form / Schnellmischergranulationsverfahren 2. Tablets with granules containing the active ingredient (I) in hydrophilized form / Schnellmischergranulationsverfahren 2.1 Tablettenzusammensetzung (in mg/Tablette)2.1 tablet composition (in mg / tablet)

Wirkstoff (I), mikronisiertActive ingredient (I), micronized 5.0 mg5.0 mg Mikrokristalline CelluloseMicrocrystalline cellulose 40.0 mg40.0 mg Laktose MonohydratLactose monohydrate 33.9 mg33.9 mg Croscarmellose (Ac-Di-Sol®, FMC)Croscarmellose (Ac-Di- Sol® , FMC) 3.0 mg3.0 mg Hydroxypropylmethylcellulose, 3 mPa·sHydroxypropylmethylcellulose, 3 mPa · s 2.0 mg2.0 mg Natriumlaurylsulfatsodium lauryl sulfate 0.5 mg0.5 mg Magnesiumstearatmagnesium stearate 0.6 mg0.6 mg Hydroxypropylmethylcellulose, 15 mPa·sHydroxypropyl methylcellulose, 15 mPa.s 1.5 mg1.5 mg Polyethylenglykol 400Polyethylene glycol 400 0.5 mg0.5 mg Eisenoxid gelbIron oxide yellow 0.1 mg0.1 mg TitandioxidTitanium dioxide 0.4 mg0.4 mg 87.5 mg87.5 mg

2.2 Herstellung2.2 Production

In einem Schnellmischer werden die Einsatzstoffe mikrokristalline Cellulose, Laktose Monohydrat und Croscarmellose gemischt (Granulatvorlage). Hydroxypropylmethylcellulose (3 mPa·s) und Natriumlaurylsulfat werden in Wasser gelöst. In diese Lösung wird der mikronisierte Wirkstoff (I) suspendiert. Die so hergestellte Suspension wird als Granulierflüssigkeit der Granulatvorlage zugegeben und mit Hilfe des schnell rotierenden Rührwerkes gleichmäßig mit der Granulatvorlage vermischt. Nach erfolgter Durchmischung wird das feuchte Granulat gesiebt (4 mm Maschenweite) und in der Wirbelschicht getrocknet. Nach Siebung des getrockneten Granulates (0.8 mm Maschenweite) wird Magnesiumstearat zugegeben und gemischt. Die so erhaltene pressfertige Mischung wird zu Tabletten mit 6 mm Durchmesser und einer Bruchfestigkeit von 50 - 100 N verpresst. Die anschließende Lackierung der Tabletten erfolgt mit Titandioxid und Eisenoxid gelb, wobei die Pigmente zuvor in einer wässrigen Lösung aus Hydroxypropyl-methylcellulose (15 mPa·s) und Polyethylenglykol suspendiert werden.In a high-speed mixer, the starting materials microcrystalline cellulose, lactose monohydrate and croscarmellose are mixed (granule template). Hydroxypropylmethyl cellulose (3 mPa.s) and sodium lauryl sulfate are dissolved in water. In this solution, the micronized drug (I) is suspended. The suspension prepared in this way is added to the granule template as granulation liquid and uniformly mixed with the granule master by means of the rapidly rotating stirrer. After mixing, the moist granules are sieved (4 mm mesh size) and dried in the fluidized bed. After sieving the dried granules (0.8 mm mesh size), magnesium stearate is added and mixed. The press-ready mixture thus obtained is compressed into tablets of 6 mm diameter and a breaking strength of 50-100 N. The subsequent coating of the tablets is carried out with titanium dioxide and iron oxide yellow, wherein the pigments are previously suspended in an aqueous solution of hydroxypropyl methylcellulose (15 mPa · s) and polyethylene glycol.

3. Herstellung von Granulaten enthaltend den Wirkstoff (I) in hydrophilisierter Form und Abfüllung als Sachets 3. Production of granules containing the active ingredient (I) in hydrophilized form and filling as sachets 3.1 Granulatzusammensetzung (in mg/Sachet)3.1 Granule composition (in mg / sachet)

Wirkstoff (I), mikronisiertActive ingredient (I), micronized 50.0 mg50.0 mg Mannitolmannitol 662.0 mg662.0 mg Croscarmellose (Ac-Di-Sol®, FMC)Croscarmellose (Ac-Di- Sol® , FMC) 15.0 mg15.0 mg Hydroxypropylmethylcellulose, 5 mPasHydroxypropylmethylcellulose, 5 mPas 15.0 mg15.0 mg Natriumlaurylsulfatsodium lauryl sulfate 1.0 mg1.0 mg Hochdisperses Siliciumdioxid (Aerosil® 200, Degussa)Colloidal anhydrous silica (Aerosil ® 200, Degussa) 2.0 mg2.0 mg Erdbeeraaroma, sprühgetrocknetStrawberry flavor, spray dried 5,0 mg5.0 mg 750.0 mg750.0 mg

3.2 Herstellung3.2 Production

Hydroxypropylmethylcellulose (5 mPa·s) und Natriumlaurylsulfat worden in Wasser gelöst. In diese Lösung wird der mikronisierte Wirkstoff (I) suspendiert. Die so hergestellte Suspension wird als Granulierflüssigkeit im Rahmen einer Wirbelschichtgranulation auf die Vorlage aus Mannitol und Croscarmellose aufgesprüht Nach Trocknung und Siebung (0.8 mm Maschenweite) des entstandenen Granulates werden hochdisperses Siliciumdioxid (Aerosil®) und Erdbeeraroma zugegeben und gemischt. Die so erhaltene Mischung wird zu jeweils 750 mg mit Hilfe einer Sachetabfüllmaschine in Sachetbeutel abgefüllt.Hydroxypropylmethylcellulose (5 mPa.s) and sodium lauryl sulfate were dissolved in water. In this solution, the micronized drug (I) is suspended. The suspension thus prepared is sprayed as a granulation liquid in a fluidized bed on the template of mannitol and croscarmellose After drying and sieving (0.8 mm mesh width) the resulting granules are added and mixed colloidal silicon dioxide (Aerosil ®), and strawberry flavor. The resulting mixture is filled into sachet bags of 750 mg each using a sachet filling machine.

4. Herstellung von Granulaten enthaltend den Wirkstoff (I) in hydrophilisierter Form und Abfüllung in Hartgelatinekapseln 4. Production of granules containing the active ingredient (I) in hydrophilized form and filling into hard gelatin capsules 4.1 Granulatzusammensetzung (in mg/Kapsel)4.1 granule composition (in mg / capsule)

Wirkstoff (I), mikronisiertActive ingredient (I), micronized 20.0 mg20.0 mg Mikrokristalline CelluloseMicrocrystalline cellulose 30.0 mg30.0 mg Laktose MonohydratLactose monohydrate 79.5 mg79.5 mg Maisstärkecorn starch 25.0 mg25.0 mg Hydroxypropylmethylcellulose, 5 mPasHydroxypropylmethylcellulose, 5 mPas 4.5 mg4.5 mg Natriumlaurylsulfatsodium lauryl sulfate 0.5 mg0.5 mg Hochdisperses Siliciumdioxid (Aerosil® 200, Degussa)Colloidal anhydrous silica (Aerosil ® 200, Degussa) 0.5 mg0.5 mg 160.0 mg160.0 mg

4.2 Herstellung4.2 Production

Hydroxypropylmethylcellulose (5 mPas) und Natriumlaurylsulfat werden in Wasser gelöst In diese Lösung wird der mikronisierte Wirkstoff (I) suspendiert. Die so hergestellte Suspension wird als Granulierflüssigkeit im Rahmen einer Wirbelschichtgranulation auf die Vorlage aus mikrokristalliner Cellulose, Laktose Monohydrat und Maisstärke aufgesprüht. Nach Trocknung und Siebung (0.8 mm Maschenweite) des entstandenen Granulates wird hochdisperses Siliciumdioxid (Aerosil®) zugegeben und gemischt. Die erhaltene Mischung wird zu jeweils 160 mg in Hartgelatinekapseln der Kapselgröße 2 abgefülltHydroxypropylmethylcellulose (5 mPas) and sodium lauryl sulfate are dissolved in water. The micronized active substance (I) is suspended in this solution. The suspension thus prepared is sprayed as a granulating liquid in a fluidized bed granulation on the template of microcrystalline cellulose, lactose monohydrate and corn starch. After drying and sieving (0.8 mm mesh width) the resulting granules is highly disperse silica (Aerosil ®) was added and mixed. The resulting mixture is filled to 160 mg each in capsule size 2 hard gelatin capsules

5. Vergleich von Tabletten mit / ohne hydrophilisiertem Wirkstoff (I) 5. Comparison of tablets with / without hydrophilised active substance (I) 5.1 Tablettenzusammensetzung, -herstellung5.1 tablet composition, preparation

Um die Tabletteneigenschaften und die verbesserte Bioverfügbarkeit von Formulierungen mit hydrophilisiertem Wirkstoff (I) zu untersuchen, werden unlackierte Tabletten mit 10 mg Wirkstoffgehalt (I) folgender Zusammensetzung hergestellt (in mg/Tablette): Wirkstoff (I), mikronisiert 10.0 mg Mikrokristalline Cellulose 40.0 mg Laktose Monohydrat 27.9 mg Croscarmellose (Ac-Di-Sol®, FMC) 3.0 mg Hydroxypropylmethylcellulose, 5 mPas 3.0 mg Natriumlaurylsulfat 0.5 mg Magnesiumstearat 0.6 mg 85.0 mg In order to investigate the tablet properties and the improved bioavailability of formulations with hydrophilized active ingredient (I), unpainted tablets with 10 mg active ingredient content (I) of the following composition are prepared (in mg / tablet): Active ingredient (I), micronized 10.0 mg Microcrystalline cellulose 40.0 mg Lactose monohydrate 27.9 mg Croscarmellose (Ac-Di- Sol® , FMC) 3.0 mg Hydroxypropylmethylcellulose, 5 mPas 3.0 mg sodium lauryl sulfate 0.5 mg magnesium stearate 0.6 mg 85.0 mg

Tablette A: hergestellt durch Direkttablettierung ohne Granulation Tablet A : prepared by direct tableting without granulation Tablette B: hergestellt durch das unter 1.2 beschriebene Wirbelschicht-granulations-/Suspensionsverfahren Tablet B : prepared by the fluidized bed granulation / suspension method described under 1.2

Die Mischung für Tablette A und das Granulat für Tablette B werden jeweils zu Tabletten mit einem Durchmesser von 6 mm und einer Bruchfestigkeit von ca. 70 - 80 N gepresst.The mixture for tablet A and the granules for tablet B are each pressed into tablets with a diameter of 6 mm and a breaking strength of about 70-80 N.

5.2 Tabletteneigenschaften5.2 Tablet properties 5.2.1 Zerfallszeit in Wasser (USP-Zerfallstester, Erweka):5.2.1 Disintegration time in water (USP decay tester, Erweka):

Tablette A:Tablet A: ca. 1.5 Minutenabout 1.5 minutes Tablette B:Tablet B: ca. 6.5 Minutenabout 6.5 minutes

5.2.2 in-vitro Freisetzung5.2.2 in vitro release

In der folgenden Tabelle 1 sind die freigesetzten Wirkstoffmengen bezogen auf den deklarierten Gesamtgehalt der Tabletten wiedergegeben: Tabelle 1: in-vitro Freisetzung 15 min 30 min 45 min 60 min Tablette A 87 % 92 % 93 % 94 % Tablette B 94 % 95 % 96 % 96 % (USP-Paddle, 900 ml Acetat-Puffer pH 4.5 + 0.5 % Natriumlaurylsulfat, 75 UpM)Table 1 below shows the quantities of active substance released based on the declared total content of the tablets: <b><i> Table 1: in vitro release </ i></b> 15 minutes 30 min 45 min 60 min Tablet A 87% 92% 93% 94% Tablet B 94% 95% 96% 96% (USP paddle, 900 ml acetate buffer pH 4.5 + 0.5% sodium lauryl sulfate, 75 rpm)

5.2.3 Bioverfügbarkeit5.2.3 Bioavailability

Zur Untersuchung der Bioverfügbarkeit wurden drei Hunden jeweils drei Tabletten A bzw. drei Tabletten B cross-over appliziert. In der folgenden Tabelle 2 sind die entsprechenden pharmakokinetischen Parameter nach oraler Gabe von 3 mg Wirkstoff (I) / kg aufgelistet: Tabelle 2: Pharmakokinetische Parameter von Wirkstoff (I) Tablette A Tier Mean geom. S.D. geom. Mean arithm. S.D. arithm. 1 2 3 AUC(0-24) [mg·h/L] 1,39 2,31 3,34 2,21 1,55 2,35 0,974 AUC(0-24)norm [kg·h/L] 0,464 0,770 1,11 0,735 1,55 0,782 0,325 Cmax [mg/L] 0,299 0,398 0,430 0,371 1,21 0,376 0,0684 Cmax,norm [kg/L] 0,0997 0,133 0,143 0,124 1,21 0,125 0,0228 C(24)/Cmax [%] 12,2 2,99 55,1 12,6 4,29 23,4 27,8 tmax [h] 1,00 1,50 0,750 1,04 1,42 1,08 0,382 Tablette B AUC(0-24) [mg·h/L] 2,82 3,03 3,73 3,17 1,16 3,19 0,476 AUC(0-24)norm [kg·h/L] 0,938 1,01 1,24 1,06 1,16 1,06 0,159 Cmax [mg/L] 0,478 0,513 0,321 0,428 1,29 0,437 0,102 Cmax,norm [kg/L] 0,159 0,171 0,107 0,143 1,29 0,146 0,0341 C(24)/Cmax [%] 26,4 1,17 93,4 14,2 9,53 40,3 47,7 tmax [h] 1,00 1,50 0,750 1,04 1,42 1,08 0,382 To investigate the bioavailability, three dogs were each given three tablets A or three tablets B cross-over. The following Table 2 lists the corresponding pharmacokinetic parameters after oral administration of 3 mg of active ingredient (I) / kg: <b><i> Table 2: Pharmacokinetic parameters of drug (I) </ i></b> Tablet A animal Mean geom. SD geom. Mean arithm. SD arithm. 1 2 3 AUC (0-24) [Mg · h / L] 1.39 2.31 3.34 2.21 1.55 2.35 0.974 AUC (0-24) norm [kg · h / L] 0.464 0,770 1.11 0.735 1.55 0.782 0,325 C max [Mg / L] 0.299 0.398 0,430 0.371 1.21 0,376 0.0684 C max, norm [Kg / L] 0.0997 0,133 0.143 0,124 1.21 0,125 0.0228 C (24) / C max [%] 12.2 2.99 55.1 12.6 4.29 23.4 27.8 t max [H] 1.00 1.50 0,750 1.04 1.42 1.08 0,382 Tablet B AUC (0-24) [Mg · h / L] 2.82 3.03 3.73 3.17 1.16 3.19 0,476 AUC (0-24) norm [kg · h / L] 0.938 1.01 1.24 1.06 1.16 1.06 0,159 C max [Mg / L] 0,478 0.513 0.321 0.428 1.29 0.437 0,102 C max, norm [Kg / L] 0,159 0.171 0,107 0.143 1.29 0.146 .0341 C (24) / C max [%] 26.4 1.17 93.4 14.2 9.53 40.3 47.7 t max [H] 1.00 1.50 0,750 1.04 1.42 1.08 0,382

Ergebnis: Trotz langsameren Zerfalls (siehe 5.2.1) und sehr ähnlicher in-vitro Freisetzung (siehe 5.2.2) von Tablette B im Vergleich zu Tablette A besitzt Tablette B deutliche Vorteile bei der Absorption und damit eine um ca. 35 % gesteigerte Bioverfügbarkeit. Gleichzeitig ist eine deutliche Abnahme der Variabilität festzustellen. Der einzige Unterschied zwischen Tablette A und Tablette B ist die Hydrophilisierung des Wirkstoffes (I) bei Tablette B mit Hilfe des Suspensionsverfahrens im Rahmen der Feuchtgranulierung.Result: Despite slower disintegration (see 5.2.1) and very similar in vitro release (see 5.2.2) of tablet B compared to tablet A, tablet B has distinct advantages in absorption and thus increased bioavailability by about 35% , At the same time, there is a significant decrease in variability. The only difference between tablet A and tablet B is the hydrophilization of the active ingredient (I) in tablet B by means of the wet granulation suspension method.

Claims (20)

  1. Process for the preparation of a solid, orally administrable pharmaceutical composition comprising 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide (I) in hydrophilized form, characterized in that
    (a) first granules comprising the active compound (I) in hydrophilized form are prepared by moist granulation
    (b) and the granules are then converted into the pharmaceutical composition, if appropriate with addition of pharmaceutically suitable additives.
  2. Process according to Claim 1, characterized in that the moist granulation method used is fluidized bed granulation.
  3. Process according to Claim 1 or 2, characterized in that the active compound (I) is employed in crystalline form.
  4. Process according to Claim 3, characterized in that the active compound (I) is employed in micronized form.
  5. Process according to one of Claims 1 to 4, characterized in that the active compound (I) suspended in the granulating liquid is introduced into the moist granulation.
  6. Process according to one of Claims 1 to 5, characterized in that the pharmaceutical composition is a tablet rapidly releasing the active compound (I).
  7. Solid, orally administrable pharmaceutical composition prepared by the process according to Claim 1.
  8. Solid, orally administrable pharmaceutical composition, comprising 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide (I) in hydrophilized form.
  9. Pharmaceutical composition according to Claim 8, comprising the active compound (I) in crystalline form.
  10. Pharmaceutical composition according to Claim 9, comprising the active compound (I) in micronized form.
  11. Pharmaceutical composition according to one of Claims 7 to 10, characterized in that the active compound (I) is present in a concentration of 1 to 60% based on the total mass of the formulation.
  12. Pharmaceutical composition according to one of Claims 7 to 11, comprising sodium lauryl sulphate as a wetting agent.
  13. Pharmaceutical composition according to Claim 12, comprising sodium lauryl sulphate in a concentration of 0.1 to 5%, based on the total mass.
  14. Pharmaceutical composition according to one of Claims 7 to 13, comprising hydroxypropylmethylcellulose as a hydrophilic binding agent.
  15. Pharmaceutical composition according to Claim 14, comprising hydroxypropyl-methylcellulose in a concentration of 1 to 15%, based on the total mass.
  16. Pharmaceutical composition according to one of Claims 7 to 15 in the form of a tablet.
  17. Pharmaceutical composition according to Claim 16 in the form of a rapid-release tablet.
  18. Pharmaceutical composition according to Claim 16 or 17, characterized in that the tablet is covered with a coating.
  19. Use of the pharmaceutical composition according to one of Claims 7 to 18 in the manufacture of a medicament for the prophylaxis and/or treatment of thromboembolic diseases.
  20. Use of 5-chloro-N({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide (I) in hydrophilized form in the manufacture of a medicament for the prophylaxis and/or treatment of thromboembolic diseases.
EP04797879.6A 2003-11-27 2004-11-13 METHOD FOR THE PRODUCTION OF A SOLID, ORALLY APPLICABLE PHARMACEUTICAL COMPOSITION COMPRISING 5-Chlor-N ( { (5-2-oxo-3- [4- (3-oxo-4-morpholinyl)-phenyl]-1, 3- oxazolidin-5-yl}-methyl)-2-thiophencarboxamide Expired - Lifetime EP1689370B2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
PL04797879T PL1689370T5 (en) 2003-11-27 2004-11-13 METHOD FOR THE PRODUCTION OF A SOLID, ORALLY APPLICABLE PHARMACEUTICAL COMPOSITION COMPRISING 5-Chlor-N ( { (5-2-oxo-3- [4- (3-oxo-4-morpholinyl)-phenyl]-1, 3- oxazolidin-5-yl}-methyl)-2-thiophencarboxamide
SI200430675T SI1689370T1 (en) 2003-11-27 2004-11-13 METHOD FOR THE PRODUCTION OF A SOLID, ORALLY APPLICABLE PHARMACEUTICAL COMPOSITION COMPRISING 5-Chlor-N ( ?í (5-2-oxo-3- ?á4- (3-oxo-4-morpholinyl)-phenyl?å-1, 3- oxazolidin-5-yl?ç-methyl)-2-thiophencarboxamide
HRP20080150TT HRP20080150T4 (en) 2003-11-27 2004-11-13 Method for the production of a solid, orally applicable pharmaceutical composition comprising 5-chlor-n({(5-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamide
SI200430675A SI1689370T2 (en) 2003-11-27 2004-11-13 METHOD FOR THE PRODUCTION OF A SOLID, ORALLY APPLICABLE PHARMACEUTICAL COMPOSITION COMPRISING 5-Chlor-N ( š (5-2-oxo-3- Š4- (3-oxo-4-morpholinyl)-phenylĆ-1, 3- oxazolidin-5-ylć-methyl)-2-thiophencarboxamide
CY20081100352T CY1107369T1 (en) 2003-11-27 2008-03-27 METHOD FOR PRODUCTION OF A SOLID, ORAL ORGANIZED PHARMACEUTICAL COMPOSITION WITH 5-CHLORO-N ({(5S) -2-OXO-3- [4- (3-OXO-1-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-1-O-O-O-O-O-O-1-O-O-O-1-O-O-1- -Oxazolidine-5-yl} -methyl) -2-thiophene-carboxamide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10355461A DE10355461A1 (en) 2003-11-27 2003-11-27 Solid, high bioavailabilty oral formulations of N-substituted 5-chloro-2-thiophene-carboxamide derivative in hydrophilized form, useful for combating thrombo-embolic diseases
PCT/EP2004/012897 WO2005060940A2 (en) 2003-11-27 2004-11-13 Method for the production of a solid, orally applicable pharmaceutical composition

Publications (3)

Publication Number Publication Date
EP1689370A2 EP1689370A2 (en) 2006-08-16
EP1689370B1 true EP1689370B1 (en) 2008-02-13
EP1689370B2 EP1689370B2 (en) 2016-09-14

Family

ID=34609342

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04797879.6A Expired - Lifetime EP1689370B2 (en) 2003-11-27 2004-11-13 METHOD FOR THE PRODUCTION OF A SOLID, ORALLY APPLICABLE PHARMACEUTICAL COMPOSITION COMPRISING 5-Chlor-N ( { (5-2-oxo-3- [4- (3-oxo-4-morpholinyl)-phenyl]-1, 3- oxazolidin-5-yl}-methyl)-2-thiophencarboxamide

Country Status (34)

Country Link
US (4) US20080026057A1 (en)
EP (1) EP1689370B2 (en)
JP (1) JP4852423B2 (en)
KR (1) KR101151117B1 (en)
CN (1) CN1886120B (en)
AR (2) AR047844A1 (en)
AT (1) ATE385782T1 (en)
AU (1) AU2004305226B2 (en)
BR (1) BRPI0416404B8 (en)
CA (1) CA2547113C (en)
CO (1) CO5690540A2 (en)
CU (1) CU23551B7 (en)
CY (1) CY1107369T1 (en)
DE (2) DE10355461A1 (en)
DK (1) DK1689370T4 (en)
EC (1) ECSP066584A (en)
ES (1) ES2300845T5 (en)
GT (1) GT200400239A (en)
HN (1) HN2004000490A (en)
HR (1) HRP20080150T4 (en)
IL (1) IL175860B2 (en)
MA (1) MA28178A1 (en)
MY (1) MY138386A (en)
NO (1) NO340156B1 (en)
NZ (1) NZ547466A (en)
PE (1) PE20050666A1 (en)
PL (1) PL1689370T5 (en)
PT (1) PT1689370E (en)
RU (2) RU2379036C2 (en)
SI (2) SI1689370T2 (en)
TW (1) TWI356702B (en)
UA (1) UA85693C2 (en)
WO (1) WO2005060940A2 (en)
ZA (1) ZA200604166B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014005934A1 (en) 2012-07-03 2014-01-09 Bayer Pharma Aktiengesellschaft Pharmaceutical administration forms comprising 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide
EP3505160A1 (en) 2017-12-31 2019-07-03 Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. Preparation of a solid pharmaceutical composition comprising rivaroxaban and production thereof
WO2022199896A1 (en) 2021-03-24 2022-09-29 Pharmathen S.A. Pharmaceutical composition comprising rivaroxaban and method of preparation thereof

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962924A1 (en) * 1999-12-24 2001-07-05 Bayer Ag Substituted oxazolidinones and their use
DE10129725A1 (en) * 2001-06-20 2003-01-02 Bayer Ag Combination therapy of substituted oxazolidinones
DE10300111A1 (en) 2003-01-07 2004-07-15 Bayer Healthcare Ag Process for the preparation of 5-chloro-N - ({(5S) -2-oxo-3- [4- (3-oxo-4-morpholinyl) phenyl] -1,3-oxazolidin-5-yl} methyl ) -2-thiophenecarboxamide
DE10355461A1 (en) 2003-11-27 2005-06-23 Bayer Healthcare Ag Solid, high bioavailabilty oral formulations of N-substituted 5-chloro-2-thiophene-carboxamide derivative in hydrophilized form, useful for combating thrombo-embolic diseases
DE102004062475A1 (en) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Solid, orally administrable, modified release pharmaceutical dosage forms
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
DE102005045518A1 (en) 2005-09-23 2007-03-29 Bayer Healthcare Ag New 5-thienylaminocarbonylmethyl-oxazolidin-2-one derivatives, useful for treating and preventing thromboembolic disease, are selective inhibitors of coagulation factor Xa
DE102005047558A1 (en) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Combination therapy of substituted oxazolidinones for the prophylaxis and treatment of cerebral circulatory disorders
DE102005047561A1 (en) * 2005-10-04 2007-04-05 Bayer Healthcare Ag Drug delivery system, useful to treat and/or prevent e.g. thromboembolic disease, comprises 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxo-4-morpholinyl)-phenyl)-1,3-oxazolidine-5-yl)-methyl)-2-thiophene carboxamide with fast release active substance
RU2578602C2 (en) 2005-10-04 2016-03-27 Байер Интеллектуэль Проперти Гмбх Method for obtaining 5-chloro-n-(5s)-2-oxo-3-[4-(3-oxo-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide in modification ii (versions)
DE102006007146A1 (en) 2006-02-16 2007-08-23 Bayer Healthcare Ag Aminoacyl prodrugs
EP2026770A1 (en) * 2006-06-12 2009-02-25 Schering Corporation Pharmaceutical formulations and compositions of a selective antagonist of either cxcr2 or both cxcr1 and cxcr2 and methods of using the same for treating inflammatory disorders
DE102006039589A1 (en) * 2006-08-24 2008-03-06 Bayer Healthcare Ag Aminoacyl prodrugs II
DE102006051625A1 (en) * 2006-11-02 2008-05-08 Bayer Materialscience Ag Combination therapy of substituted oxazolidinones
JPWO2008066102A1 (en) * 2006-11-30 2010-03-11 武田薬品工業株式会社 Sustained release formulation
MX2009006873A (en) * 2006-12-22 2009-07-03 Schering Corp Disintegration promoters in solid dose wet granulation formulations.
JP5275815B2 (en) * 2006-12-26 2013-08-28 塩野義製薬株式会社 Orally disintegrating tablets and bitterness-suppressing preparations containing risperidone
JP4463875B2 (en) 2007-03-29 2010-05-19 第一三共株式会社 Pharmaceutical composition
DE102007028407A1 (en) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituted oxazolidinones and their use
DE102007028319A1 (en) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituted oxazolidinones and their use
KR101353878B1 (en) * 2008-06-05 2014-01-20 가부시키가이샤 브레인베이스 Bone prosthetic material and method of producing the same
EP2303240A1 (en) * 2008-07-08 2011-04-06 Ratiopharm GmbH Pharmaceutical compositions comprising 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
WO2010017948A2 (en) * 2008-08-11 2010-02-18 Ratiopharm Gmbh Pharmaceutical compositions with modified release properties comprising 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl)-methyl)-2-thiophencarboxamid
US7816355B1 (en) * 2009-04-28 2010-10-19 Apotex Pharmachem Inc Processes for the preparation of rivaroxaban and intermediates thereof
US20100287817A1 (en) * 2009-05-14 2010-11-18 Fmc Corporation Method for Ant Control
HRP20161617T4 (en) 2009-06-18 2019-06-28 Krka, Tovarna Zdravil, D.D., Novo Mesto SOLID PHARMACEUTICAL COMPOSITION CONTAINING RIVAROXABAN
EP2266541A1 (en) 2009-06-18 2010-12-29 Krka Tovarna Zdravil, D.D., Novo Mesto Solid pharmaceutical composition comprising rivaroxaban
US20120231076A1 (en) * 2009-10-06 2012-09-13 Ratiopharm Gmbh Pharmaceutical compositions comprising rivaroxaban
EP2308472A1 (en) 2009-10-06 2011-04-13 ratiopharm GmbH Pharmaceutical compositions comprising rivaroxaban
SI3246021T1 (en) * 2010-02-25 2020-03-31 Bristol-Myers Squibb Holdings Ireland Unlimited Company Apixaban formulations
DE102010028362A1 (en) 2010-04-29 2011-11-03 Bayer Schering Pharma Aktiengesellschaft manufacturing
EP2404920A1 (en) 2010-07-06 2012-01-11 Sandoz AG Crystalline form of Rivaroxaban dihydrate
WO2012027222A1 (en) * 2010-08-24 2012-03-01 Rutgers, The State University Of New Jersey Formulation and manufacture of pharmaceuticals by impregnation onto porous carriers
DE102010063127A1 (en) 2010-12-15 2012-06-21 Bayer Schering Pharma Aktiengesellschaft Liquid, orally administrable pharmaceutical compositions containing 5-chloro-N - ({(5S) -2-oxo-3- [4- (3-oxo-4-morpholinyl) -phenyl] -1,3-oxazolidin-5-yl } -methyl) -2-thiophenecarboxamide
WO2013022924A1 (en) 2011-08-08 2013-02-14 Teva Pharmaceutical Industries Ltd. Pharmaceutical formulations
EP2808011A1 (en) 2013-05-29 2014-12-03 Sandoz Ag Process for the preparation of a pharmaceutical composition comprising Rivaroxaban
CN104337787B (en) * 2013-08-06 2018-09-07 江苏豪森药业集团有限公司 Pharmaceutical preparation containing razaxaban
CN103550165B (en) * 2013-10-19 2019-07-16 浙江华海药业股份有限公司 A kind of pharmaceutical composition and preparation method thereof containing razaxaban
CN104721156B (en) * 2013-12-18 2020-05-01 山东新时代药业有限公司 Rivaroxaban-containing tablet
WO2015124995A1 (en) 2014-02-19 2015-08-27 Aurobindo Pharma Ltd Solid dosage forms of rivaroxaban
CN104887633B (en) * 2014-03-04 2019-01-29 山东新时代药业有限公司 A kind of razaxaban tablet and preparation method thereof
CN105078997A (en) * 2014-05-19 2015-11-25 广东东阳光药业有限公司 Rivaroxaban pharmaceutical composition and preparation method thereof
CN104173313B (en) * 2014-08-25 2017-05-17 杭州朱养心药业有限公司 Rivaroxaban troche pharmaceutical composition
KR102271862B1 (en) 2014-12-31 2021-07-01 한미약품 주식회사 An oral solid formulation containing rivaroxaban
WO2016145375A1 (en) * 2015-03-11 2016-09-15 Plasmology4, Inc. Container treatment system
CN105078915A (en) * 2015-08-27 2015-11-25 江苏中邦制药有限公司 Rivaroxaban tablets and preparation method for same
CN105287414A (en) * 2015-10-21 2016-02-03 南京百迪尔生物医药有限公司 Solid drug composition containing rivaroxaban and preparation method thereof
CN105267169B (en) * 2015-12-07 2018-03-30 石家庄康贺威药业有限公司 A kind of razaxaban tablet and preparation method thereof
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
KR20180118719A (en) 2016-03-04 2018-10-31 다이호야쿠힌고교 가부시키가이샤 Preparations and compositions for the treatment of malignant tumors
WO2018007945A1 (en) * 2016-07-05 2018-01-11 Alphamed Formulations Pvt. Ltd Solid composition containing oral anticoagulant
CN106109434B (en) * 2016-08-26 2019-04-05 乐普药业股份有限公司 A kind of razaxaban tablet and preparation method thereof
JP6574041B2 (en) * 2017-12-15 2019-09-11 エルメッド株式会社 Rivaroxaban-containing pharmaceutical composition
US10828310B2 (en) 2018-02-02 2020-11-10 Bayer Pharma Aktiengesellschaft Reducing the risk of cardiovascular events
AU2019239404B2 (en) 2018-03-19 2021-12-23 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition including sodium alkyl sulfate
CN108864069B (en) * 2018-05-03 2021-04-20 华东理工大学 A kind of rivaroxaban microparticle and its preparation method and application
GR1009619B (en) * 2018-05-09 2019-10-23 Φαρμαζακ Α.Φ.Ε.Β.Ε. Pharmaceutical composition containing rivaroxaban and method for the preparation thereof
JP2020029455A (en) * 2018-08-20 2020-02-27 大原薬品工業株式会社 Solid preparation containing pulverized rivaroxaban
CN112601606A (en) * 2018-08-30 2021-04-02 勃林格殷格翰国际有限公司 Novel, lean and environmentally friendly granulation process
WO2020101587A1 (en) 2018-11-16 2020-05-22 Santa Farma İlaç Sanayi̇ A.Ş. Oral formulations comprising rivaroxaban
JP7305527B2 (en) * 2018-11-30 2023-07-10 大原薬品工業株式会社 Solid formulation containing rivaroxaban and sweetener
JP7641098B2 (en) * 2019-08-30 2025-03-06 日本ジェネリック株式会社 Rivaroxaban-containing tablets
CN112675136B (en) * 2019-10-18 2023-05-16 苏州特瑞药业股份有限公司 Composition for reducing bleeding risk of rivaroxaban and preparation method thereof
KR102290670B1 (en) 2019-12-30 2021-08-18 단국대학교 천안캠퍼스 산학협력단 Composition for oral solid preparation of rivaroxaban using self-nanoemulsifying drug delivery system and methods for their preparation
US20210267908A1 (en) * 2020-03-02 2021-09-02 Mankind Pharma Ltd. Pharmaceutical compositions of rivaroxaban
EP4208462A4 (en) * 2020-09-05 2024-09-11 Inventia Healthcare Limited COMPOSITIONS OF RIVAROXABAN
JP7511596B2 (en) * 2021-03-10 2024-07-05 日本ジェネリック株式会社 Rivaroxaban-containing tablets
CN113425729B (en) * 2021-06-24 2022-11-15 上海奥全生物医药科技有限公司 Rivaroxaban-containing pharmaceutical composition and application thereof
WO2023067620A1 (en) * 2021-10-18 2023-04-27 Unison Pharmaceuticals Pvt. Ltd. Orally disintegrating pharmaceutical compositions of rivaroxaban
EP4504207A1 (en) 2022-04-08 2025-02-12 Intas Pharmaceuticals Ltd. An orodispersible tablet of rivaroxaban
CN114886867A (en) * 2022-06-16 2022-08-12 北京四环制药有限公司 Rivaroxaban pharmaceutical composition with high stability and preparation method thereof
CN115590856A (en) * 2022-10-31 2023-01-13 南京海纳医药科技股份有限公司（Cn） Rivaroxaban-containing pharmaceutical composition and preparation method thereof

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2811555A (en) 1955-05-02 1957-10-29 Eastman Kodak Co Reduction of 2-nitroso-5-diethylaminotoluene
US3279880A (en) 1965-07-12 1966-10-18 Eastman Kodak Co Polyester textile material dyed with 1-hydroxy-4-n-p-(2'-pyrrolidonyl-1-) phenyl-amino anthraquinones
LU80081A1 (en) 1977-08-26 1979-05-15 Delalande Sa NEW HYDROXYMETHYL-5 OXAZOLIDINONES-2, THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC APPLICATION
US4128654A (en) 1978-02-10 1978-12-05 E. I. Du Pont De Nemours And Company 5-Halomethyl-3-phenyl-2-oxazolidinones
US4500519A (en) 1978-11-06 1985-02-19 Choay S.A. Mucopolysaccharides having biological properties, preparation and method of use
US4344934A (en) * 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
JPS5611061A (en) 1979-07-07 1981-02-04 Seikichi Nakajima Water circulation electrolytic device
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
HU190072B (en) 1983-03-11 1986-08-28 Biogal Gyogyszergyar,Hu Process for production of medical preparatives with sinergetic influence
NZ206600A (en) 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
ES8506659A1 (en) 1983-06-07 1985-08-01 Du Pont Aminomethyl oxooxazolidinyl benzene derivatives useful as antibacterial agents.
DE3433239A1 (en) * 1984-09-11 1986-03-20 Bayer Ag, 5090 Leverkusen SOLID PHARMACEUTICAL PREPARATION CONTAINING NITRENDIPINE AND METHOD FOR THE PRODUCTION THEREOF
US4977173A (en) 1987-10-21 1990-12-11 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl ethenylbenzene derivatives useful as antibacterial agents
EP0316594B1 (en) 1987-10-21 1993-09-29 The Du Pont Merck Pharmaceutical Company Aminomethyl oxooxazolidinyl ethenylbenzene derivatives useful as antibacterial agents
DE3822650A1 (en) 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh NEW DIPHOSPHONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
US4948801A (en) 1988-07-29 1990-08-14 E. I. Du Pont De Nemours And Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US5254577A (en) 1988-07-29 1993-10-19 The Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
TW212139B (en) 1991-04-15 1993-09-01 Yamanouchi Pharma Co Ltd
CA2119556C (en) 1991-11-01 2004-07-06 Michael Robert Barbachyn Substituted aryl- and heteroaryl-phenyloxazolidinones
SK283420B6 (en) 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimicrobial oxazolidinones containing substituted diazine groups
US5349045A (en) 1993-01-26 1994-09-20 United States Surgical Corporation Polymer derived from cyclic amide and medical devices manufactured therefrom
DK0623615T3 (en) 1993-05-01 1999-12-13 Merck Patent Gmbh Adhesion receptor antagonists
US5688792A (en) 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
DE4332384A1 (en) 1993-09-23 1995-03-30 Merck Patent Gmbh Adhesion receptor antagonists III
ES2163004T3 (en) 1995-02-03 2002-01-16 Upjohn Co PHENYLOXAZOLIDINONE REPLACED BY A HETEROAROMATIC RING AS AN ANTIMICROBIAL AGENT.
HRP960159A2 (en) 1995-04-21 1997-08-31 Bayer Ag Benzocyclopentane oxazolidinones containing heteroatoms
NZ286920A (en) 1995-07-03 1997-06-24 Sankyo Co Use of combination of hmg-coa reductase inhibitors and of insulin sensitizers for the prevention/treatment of arteriosclerosis or xanthoma
DE19524765A1 (en) 1995-07-07 1997-01-09 Boehringer Mannheim Gmbh New oxazolidinone derivatives, processes for their preparation and medicaments containing these compounds
CA2228647A1 (en) 1995-09-01 1997-03-13 Pharmacia & Upjohn Company Phenyloxazolidinones having a c-c bond to 4-8 membered heterocyclic rings
EP1019385B1 (en) 1995-09-15 2004-01-14 PHARMACIA &amp; UPJOHN COMPANY Aminoaryl oxazolidinone n-oxides
DE19601264A1 (en) 1996-01-16 1997-07-17 Bayer Ag Pyrido-annellated thienyl and furanyl oxazolidinones
DE19604223A1 (en) 1996-02-06 1997-08-07 Bayer Ag New substituted oxazolidinones
HRP970049A2 (en) 1996-02-06 1998-04-30 Bayer Ag New heteroaryl oxazolidinones
NZ332585A (en) * 1996-05-01 2000-04-28 Ortho Mcneil Pharm Inc Carboxamide derivatives of pyrrolidine, piperidine and hexahydroazepine for the treatment of thrombosis disorders
CN1228693A (en) 1996-06-28 1999-09-15 先灵公司 Oral compositions containing triazole antifungal compounds
GB9614238D0 (en) 1996-07-06 1996-09-04 Zeneca Ltd Chemical compounds
DK1175902T3 (en) 1996-07-15 2005-12-19 Sankyo Co Application of CS-866 (olmesartan) to the manufacture of a medicament for the treatment of arteriosclerosis
FR2758459B1 (en) * 1997-01-17 1999-05-07 Pharma Pass FENOFIBRATE PHARMACEUTICAL COMPOSITION HAVING HIGH BIODAVAILABILITY AND PROCESS FOR PREPARING THE SAME
FR2759585B1 (en) * 1997-02-17 1999-06-11 Sanofi Sa PHARMACEUTICAL FORMULATIONS PRESENTED IN A DRY FORM FOR THE ORAL ADMINISTRATION OF A CYCLIC QUATERNARY AMMONIUM COMPOUND
US5935724A (en) 1997-04-04 1999-08-10 Wilson Greatbatch Ltd. Electrochemical cell having multiplate electrodes with differing discharge rate regions
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
NZ501412A (en) 1997-05-30 2001-11-30 Upjohn Co Oxazolidinone antibacterial agents having a thiocarbonyl functionality
CA2294293A1 (en) 1997-07-11 1999-01-21 Pharmacia & Upjohn Company Thiadiazolyl and oxadiazolyl phenyl oxazolidinone antibacterial agents
DE19730847A1 (en) 1997-07-18 1999-01-28 Bayer Ag Tricyclically substituted oxazolidinones
DE19747261A1 (en) 1997-10-25 1999-04-29 Bayer Ag Single-chamber osmotic pharmaceutical release system
AU739055B2 (en) 1997-11-12 2001-10-04 Pharmacia & Upjohn Company Oxazolidinone derivatives and pharmaceutical compositions
US6083967A (en) 1997-12-05 2000-07-04 Pharmacia & Upjohn Company S-oxide and S,S-dioxide tetrahydrothiopyran phenyloxazolidinones
DE19755268A1 (en) 1997-12-12 1999-06-17 Merck Patent Gmbh Benzamidine derivatives
DE19802239A1 (en) 1998-01-22 1999-07-29 Bayer Ag New oxazolidinone derivatives useful as antimicrobial agents against Gram-positive and some Gram-negative bacteria, mycobacteria, etc.
EP1049682A1 (en) 1998-01-23 2000-11-08 Versicor, Inc. Oxazolidinone combinatorial libraries, compositions and methods of preparation
HUP0101810A3 (en) 1998-01-27 2002-05-28 Aventis Pharm Prod Inc Substituted oxoazaheterocyclyl factor xa inhibitors and pharmaceutical compositions containing them
DE19805117A1 (en) 1998-02-09 1999-08-12 Bayer Ag New oxazolidinones with azole-containing tricycles
US20010029351A1 (en) 1998-04-16 2001-10-11 Robert Falotico Drug combinations and delivery devices for the prevention and treatment of vascular disease
EP1077718B1 (en) 1998-05-18 2002-08-14 PHARMACIA &amp; UPJOHN COMPANY Enhancement of oxazolidinone antibacterial agents activity by arginine derivatives
DE19842753A1 (en) 1998-09-18 2000-03-23 Bayer Ag Multiple-unit retard oral dosage formulation having controlled release independent of agitation and food effect, containing particles of combination of drug and hydroxypropyl cellulose
SA99191255B1 (en) 1998-11-30 2006-11-25 جي دي سيرل اند كو celecoxib compounds
US6413981B1 (en) 1999-08-12 2002-07-02 Ortho-Mcneil Pharamceutical, Inc. Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods
PE20010851A1 (en) 1999-12-14 2001-08-17 Upjohn Co BENZOIC ACID ESTERS OF OXAZOLIDINONES HAVING A HYDROXYACETILPIPERAZINE SUBSTITUENT
EP1242417A1 (en) 1999-12-21 2002-09-25 PHARMACIA &amp; UPJOHN COMPANY Oxazolidinones having a sulfoximine functionality and their use as antimicrobial agents
DE19962924A1 (en) * 1999-12-24 2001-07-05 Bayer Ag Substituted oxazolidinones and their use
CA2395948A1 (en) 1999-12-28 2001-07-05 Ajinomoto Co., Inc. Crystal of aspartame derivative
US6514529B2 (en) * 2000-03-22 2003-02-04 Pharmacia & Upjohn Company Oxazolidinone tablet formulation
PE20020300A1 (en) 2000-08-22 2002-05-10 Pharmacia Corp COMPOSITION OF SOLUTION OF AN ANTIBIOTIC DRUG BASED ON OXAZOLIDINONE WITH IMPROVEMENT OF DRUG LOAD
KR100415318B1 (en) 2000-09-23 2004-01-16 탁승호 Level and vertical line indicator using laser beams
WO2002038126A2 (en) 2000-11-08 2002-05-16 Aeromatic-Fielder Ag A process for production of particles for pharmaceutical compositions having increased bioavailability
US20040092480A1 (en) 2001-01-30 2004-05-13 Kentaro Fujinaga Medicinal composition
DE10105989A1 (en) 2001-02-09 2002-08-14 Bayer Ag Substituted oxazolidinones and their use
DE10110438A1 (en) 2001-03-05 2002-09-19 Bayer Ag Substituted 2-oxy-3,5-dicyano-4-aryl-6-aminopyridines and their use
DE10110747A1 (en) 2001-03-07 2002-09-12 Bayer Ag Substituted 2,6-diamino-3,5-dicyano-4-aryl-pyridines and their use
DE10110754A1 (en) 2001-03-07 2002-09-19 Bayer Ag Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use
DE10115922A1 (en) 2001-03-30 2002-10-10 Bayer Ag Cyclically substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use
DE10115945A1 (en) 2001-03-30 2002-10-02 Bayer Ag Substituted 2-carba-3,5-dicyano-4-aryl-6-aminopyridines and their use
DE10129725A1 (en) 2001-06-20 2003-01-02 Bayer Ag Combination therapy of substituted oxazolidinones
DE10134481A1 (en) 2001-07-16 2003-01-30 Bayer Ag Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use
DE10152460A1 (en) * 2001-10-24 2003-05-08 Bayer Ag stents
DE10238113A1 (en) 2001-12-11 2003-06-18 Bayer Ag New 2-substituted methylthio-dicyanopyridine derivatives, useful for treating or preventing e.g. cardiovascular disease and inflammation, are adenosine A1 receptor agonists
US20030161882A1 (en) 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
DE10300111A1 (en) 2003-01-07 2004-07-15 Bayer Healthcare Ag Process for the preparation of 5-chloro-N - ({(5S) -2-oxo-3- [4- (3-oxo-4-morpholinyl) phenyl] -1,3-oxazolidin-5-yl} methyl ) -2-thiophenecarboxamide
DE10355461A1 (en) 2003-11-27 2005-06-23 Bayer Healthcare Ag Solid, high bioavailabilty oral formulations of N-substituted 5-chloro-2-thiophene-carboxamide derivative in hydrophilized form, useful for combating thrombo-embolic diseases
DE102004002044A1 (en) 2004-01-15 2005-08-04 Bayer Healthcare Ag manufacturing
DE102004062475A1 (en) 2004-12-24 2006-07-06 Bayer Healthcare Ag Solid, orally administrable, modified release pharmaceutical dosage forms
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
DE102005045518A1 (en) 2005-09-23 2007-03-29 Bayer Healthcare Ag New 5-thienylaminocarbonylmethyl-oxazolidin-2-one derivatives, useful for treating and preventing thromboembolic disease, are selective inhibitors of coagulation factor Xa
DE102005047561A1 (en) 2005-10-04 2007-04-05 Bayer Healthcare Ag Drug delivery system, useful to treat and/or prevent e.g. thromboembolic disease, comprises 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxo-4-morpholinyl)-phenyl)-1,3-oxazolidine-5-yl)-methyl)-2-thiophene carboxamide with fast release active substance
DE102005047558A1 (en) 2005-10-04 2008-02-07 Bayer Healthcare Ag Combination therapy of substituted oxazolidinones for the prophylaxis and treatment of cerebral circulatory disorders
RU2578602C2 (en) 2005-10-04 2016-03-27 Байер Интеллектуэль Проперти Гмбх Method for obtaining 5-chloro-n-(5s)-2-oxo-3-[4-(3-oxo-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide in modification ii (versions)
DE102005048824A1 (en) 2005-10-10 2007-04-12 Bayer Healthcare Ag Treatment and prophylaxis of microangiopathies

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014005934A1 (en) 2012-07-03 2014-01-09 Bayer Pharma Aktiengesellschaft Pharmaceutical administration forms comprising 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide
EP3505160A1 (en) 2017-12-31 2019-07-03 Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. Preparation of a solid pharmaceutical composition comprising rivaroxaban and production thereof
EP4257136A2 (en) 2017-12-31 2023-10-11 Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. Preparation of a solid pharmaceutical composition comprising rivaroxaban and production thereof
WO2022199896A1 (en) 2021-03-24 2022-09-29 Pharmathen S.A. Pharmaceutical composition comprising rivaroxaban and method of preparation thereof

Also Published As

Publication number Publication date
CN1886120A (en) 2006-12-27
BRPI0416404A (en) 2007-01-09
KR101151117B1 (en) 2012-06-01
RU2009127302A (en) 2011-01-27
ECSP066584A (en) 2006-10-17
PL1689370T3 (en) 2008-07-31
CO5690540A2 (en) 2006-10-31
US20170007612A1 (en) 2017-01-12
CA2547113C (en) 2012-01-24
PE20050666A1 (en) 2005-12-02
DK1689370T4 (en) 2017-01-02
CA2547113A1 (en) 2005-07-07
HK1099518A1 (en) 2007-08-17
HN2004000490A (en) 2008-06-24
RU2379036C2 (en) 2010-01-20
US9402851B2 (en) 2016-08-02
KR20060117330A (en) 2006-11-16
ES2300845T5 (en) 2017-05-16
IL175860B2 (en) 2024-01-01
DE502004006218D1 (en) 2008-03-27
US20080026057A1 (en) 2008-01-31
RU2006122599A (en) 2008-01-10
NZ547466A (en) 2009-12-24
UA85693C2 (en) 2009-02-25
ZA200604166B (en) 2007-10-31
US20150037415A1 (en) 2015-02-05
NO340156B1 (en) 2017-03-13
TWI356702B (en) 2012-01-21
SI1689370T1 (en) 2008-06-30
BRPI0416404B8 (en) 2021-05-25
TW200529859A (en) 2005-09-16
WO2005060940A3 (en) 2006-03-30
ATE385782T1 (en) 2008-03-15
EP1689370B2 (en) 2016-09-14
IL175860A0 (en) 2006-10-05
NO20062942L (en) 2006-06-23
JP2007512274A (en) 2007-05-17
AR047844A1 (en) 2006-03-01
RU2493850C2 (en) 2013-09-27
GT200400239A (en) 2005-07-12
IL175860A (en) 2015-11-30
PL1689370T5 (en) 2017-09-29
AU2004305226B2 (en) 2010-06-17
AR104840A2 (en) 2017-08-16
ES2300845T3 (en) 2008-06-16
JP4852423B2 (en) 2012-01-11
WO2005060940A2 (en) 2005-07-07
CN1886120B (en) 2010-08-11
DK1689370T3 (en) 2008-06-09
MA28178A1 (en) 2006-09-01
PT1689370E (en) 2008-05-09
HRP20080150T3 (en) 2008-04-30
BRPI0416404B1 (en) 2018-08-07
CU23551B7 (en) 2010-07-20
CY1107369T1 (en) 2012-12-19
US20140248349A1 (en) 2014-09-04
US9415053B2 (en) 2016-08-16
MY138386A (en) 2009-05-29
DE10355461A1 (en) 2005-06-23
HRP20080150T4 (en) 2016-12-16
EP1689370A2 (en) 2006-08-16
SI1689370T2 (en) 2017-01-31
AU2004305226A1 (en) 2005-07-07

Similar Documents

Publication Publication Date Title
EP1689370B1 (en) METHOD FOR THE PRODUCTION OF A SOLID, ORALLY APPLICABLE PHARMACEUTICAL COMPOSITION COMPRISING 5-Chlor-N ( { (5-2-oxo-3- [4- (3-oxo-4-morpholinyl)-phenyl]-1, 3- oxazolidin-5-yl}-methyl)-2-thiophencarboxamide
EP1830855B1 (en) Solid, orally applicable pharmaceutical administration forms containing rivaroxaban having modified release
JP5401327B2 (en) Tablets with improved dissolution
EP1957048A2 (en) Solid orally administerable pharmaceutical dosage forms with rapid active principle release
JP2005526738A (en) Dosage form for oral administration of drugs with low solubility
EP2595607A2 (en) Medicinal drug for oral administration comprising a mixture of silodosin and a basic copolymer
TW200848056A (en) Solid dispersion of a neurokinin antagonist
EP4103157A1 (en) Pharmaceutical composition comprising linagliptin and metformin
EP1663162B1 (en) Orally administrable dosage form for poorly soluble acids and amphoteric active ingredients
CN114053421A (en) A kind of composition of thrombopoietin receptor agonist and preparation method thereof
EP1686965A2 (en) Solid pharmaceutical preparation form
WO2015055564A1 (en) Pharmaceutical dosage forms containing sodium-1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1h-1,2,3-triazol-1-yl)-1h-pyrazol-5-olate
HK1151991B (en) Tablet having improved elution properties
MXPA06005846A (en) Method for the production of a solid, orally applicable pharmaceutical composition
CN101252919A (en) Tablets with Improved Dissolution Profiles

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK YU

17P Request for examination filed

Effective date: 20061002

RAX Requested extension states of the european patent have changed

Extension state: LV

Payment date: 20061002

Extension state: HR

Payment date: 20061002

Extension state: LT

Payment date: 20061002

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LU MC NL PL PT RO SE SI SK TR

RAX Requested extension states of the european patent have changed

Extension state: HR

Payment date: 20061002

Extension state: LV

Payment date: 20061002

Extension state: LT

Payment date: 20061002

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RTI1 Title (correction)

Free format text: METHOD FOR THE PRODUCTION OF A SOLID, ORALLY APPLICABLE PHARMACEUTICAL COMPOSITION COMPRISING 5-CHLOR-N ( ( (5-2-OXO-3- (4- (3-OXO-4-MORPHOLINYL)-PHENYL)-1, 3- OXAZOLIDIN-5-YL)-M

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: HR LT LV

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: GERMAN

REF Corresponds to:

Ref document number: 502004006218

Country of ref document: DE

Date of ref document: 20080327

Kind code of ref document: P

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20080150

Country of ref document: HR

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM & CO. AG PATENT- UND MARKENANWAELTE VSP

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20080150

Country of ref document: HR

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20080428

GBT Gb: translation of ep patent filed (gb section 77(6)(a)/1977)

Effective date: 20080423

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20080401079

Country of ref document: GR

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E001908

Country of ref document: EE

Effective date: 20080402

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2300845

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

ET Fr: translation filed
REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E003568

Country of ref document: HU

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

26 Opposition filed

Opponent name: RATIOPHARM GMBH

Effective date: 20081112

NLR1 Nl: opposition has been filed with the epo

Opponent name: RATIOPHARM GMBH

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

REG Reference to a national code

Ref country code: CH

Ref legal event code: PUE

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT

Free format text: BAYER HEALTHCARE AG# #51368 LEVERKUSEN (DE) -TRANSFER TO- BAYER SCHERING PHARMA AKTIENGESELLSCHAFT#MUELLERSTRASSE 178#13353 BERLIN (DE)

REG Reference to a national code

Ref country code: EE

Ref legal event code: GB1A

Ref document number: E001908

Country of ref document: EE

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT

REG Reference to a national code

Ref country code: HU

Ref legal event code: FH1C

Free format text: FORMER REPRESENTATIVE(S): KERENY JUDIT, DANUBIA SZABADALMI ES JOGI IRODA KFT., HU

Representative=s name: DANUBIA SZABADALMI ES JOGI IRODA KFT., HU

Ref country code: HU

Ref legal event code: GB9C

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE

Free format text: FORMER OWNER(S): BAYER HEALTHCARE AG, DE

NLT2 Nl: modifications (of names), taken from the european patent patent bulletin

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT

Effective date: 20090624

REG Reference to a national code

Ref country code: SI

Ref legal event code: SP73

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT; DE

Effective date: 20090723

NLS Nl: assignments of ep-patents

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT

Effective date: 20090918

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

REG Reference to a national code

Ref country code: PT

Ref legal event code: PC4A

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE

Effective date: 20100415

REG Reference to a national code

Ref country code: HR

Ref legal event code: PPPP

Ref document number: P20080150

Country of ref document: HR

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE

REG Reference to a national code

Ref country code: SK

Ref legal event code: PC4A

Ref document number: E 3201

Country of ref document: SK

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, BERL, DE

Free format text: FORMER OWNER: BAYER HEALTHCARE AG, LEVERKUSEN, DE

Effective date: 20100615

APBM Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNO

APBP Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2O

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

APAW Appeal reference deleted

Free format text: ORIGINAL CODE: EPIDOSDREFNO

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: BAYER PHARMA AKTIENGESELLSCHAFT

APBQ Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3O

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 502004006218

Country of ref document: DE

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE

Free format text: FORMER OWNER: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, 13353 BERLIN, DE

Effective date: 20120612

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: BAYER INTELLECTUAL PROPERTY GMBH

REG Reference to a national code

Ref country code: CH

Ref legal event code: PUE

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE

Free format text: FORMER OWNER: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

REG Reference to a national code

Ref country code: PT

Ref legal event code: PC4A

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE

Effective date: 20130206

BECH Be: change of holder

Owner name: BAYER INTELLECTUAL PROPERTY G.M.B.H.

Effective date: 20130211

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 502004006218

Country of ref document: DE

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE

Free format text: FORMER OWNER: BAYER PHARMA AKTIENGESELLSCHAFT, 13353 BERLIN, DE

Effective date: 20130410

REG Reference to a national code

Ref country code: HU

Ref legal event code: FH1C

Free format text: FORMER REPRESENTATIVE(S): KERENY JUDIT, DANUBIA SZABADALMI ES JOGI IRODA KFT., HU

Representative=s name: DANUBIA SZABADALMI ES JOGI IRODA KFT., HU

Ref country code: HU

Ref legal event code: GB9C

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE

Free format text: FORMER OWNER(S): BAYER HEALTHCARE AG, DE; BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE

REG Reference to a national code

Ref country code: HR

Ref legal event code: PNAN

Ref document number: P20080150

Country of ref document: HR

Owner name: BAYER PHARMA AG, DE

REG Reference to a national code

Ref country code: SK

Ref legal event code: TC4A

Ref document number: E 3201

Country of ref document: SK

Owner name: BAYER PHARMA AKTIENGESELLSCHAFT, BERLIN, DE

Effective date: 20130507

Ref country code: SK

Ref legal event code: PC4A

Ref document number: E 3201

Country of ref document: SK

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, MONHEIM AM R, DE

Free format text: FORMER OWNER: BAYER PHARMA AKTIENGESELLSCHAFT, BERLIN, DE

Effective date: 20130226

REG Reference to a national code

Ref country code: NL

Ref legal event code: TD

Effective date: 20130625

Ref country code: NL

Ref legal event code: SD

Effective date: 20130625

REG Reference to a national code

Ref country code: HR

Ref legal event code: PPPP

Ref document number: P20080150

Country of ref document: HR

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20131212 AND 20131218

REG Reference to a national code

Ref country code: AT

Ref legal event code: PC

Ref document number: 385782

Country of ref document: AT

Kind code of ref document: T

Owner name: BAYER IINTELLECTUAL PROPERTY GMBH, DE

Effective date: 20131218

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

R26 Opposition filed (corrected)

Opponent name: RATIOPHARM GMBH

Effective date: 20081112

APBU Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9O

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

PUAH Patent maintained in amended form

Free format text: ORIGINAL CODE: 0009272

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT MAINTAINED AS AMENDED

27A Patent maintained in amended form

Effective date: 20160914

AK Designated contracting states

Kind code of ref document: B2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: HR LT LV

REG Reference to a national code

Ref country code: DE

Ref legal event code: R102

Ref document number: 502004006218

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: AELC

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

REG Reference to a national code

Ref country code: EE

Ref legal event code: LD4A

Ref document number: E001908

Country of ref document: EE

REG Reference to a national code

Ref country code: HR

Ref legal event code: T4IZ

Ref document number: P20080150

Country of ref document: HR

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: DK

Ref legal event code: T4

Effective date: 20161220

REG Reference to a national code

Ref country code: SE

Ref legal event code: RPEO

REG Reference to a national code

Ref country code: SK

Ref legal event code: T5

Ref document number: E 3201

Country of ref document: SK

REG Reference to a national code

Ref country code: ES

Ref legal event code: DC2A

Ref document number: 2300845

Country of ref document: ES

Kind code of ref document: T5

Effective date: 20170516

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20160403020

Country of ref document: GR

Effective date: 20170410

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20080150

Country of ref document: HR

Payment date: 20181026

Year of fee payment: 15

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20080150

Country of ref document: HR

Payment date: 20191024

Year of fee payment: 16

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20080150

Country of ref document: HR

Payment date: 20201104

Year of fee payment: 17

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20080150

Country of ref document: HR

Payment date: 20211105

Year of fee payment: 18

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20080150

Country of ref document: HR

Payment date: 20221108

Year of fee payment: 19

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230507

REG Reference to a national code

Ref country code: HR

Ref legal event code: PNAN

Ref document number: P20080150

Country of ref document: HR

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE

REG Reference to a national code

Ref country code: LU

Ref legal event code: HC

Owner name: BAYER INTELLECTUAL PROPERTY GMBH; DE

Free format text: FORMER OWNER: BAYER INTELLECTUAL PROPERTY GMBH

Effective date: 20230710

REG Reference to a national code

Ref country code: SK

Ref legal event code: TC4A

Ref document number: E 3201

Country of ref document: SK

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, MONHEIM AM R, DE

Effective date: 20230725

REG Reference to a national code

Ref country code: EE

Ref legal event code: HE1A

Ref document number: E001908

Country of ref document: EE

REG Reference to a national code

Ref country code: BE

Ref legal event code: PD

Owner name: BAYER INTELLECTUAL PROPERTY GMBH; DE

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), OTHER; FORMER OWNER NAME: BAYER INTELLECTUAL PROPERTY GMBH

Effective date: 20230810

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20080150

Country of ref document: HR

Payment date: 20231030

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20231026

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20231026

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SK

Payment date: 20231024

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20231026

Year of fee payment: 20

Ref country code: GB

Payment date: 20231019

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20231027

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20231207

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IS

Payment date: 20231107

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20231110

Year of fee payment: 20

Ref country code: SI

Payment date: 20231025

Year of fee payment: 20

Ref country code: SE

Payment date: 20231026

Year of fee payment: 20

Ref country code: RO

Payment date: 20231026

Year of fee payment: 20

Ref country code: PT

Payment date: 20231102

Year of fee payment: 20

Ref country code: IT

Payment date: 20231026

Year of fee payment: 20

Ref country code: IE

Payment date: 20231123

Year of fee payment: 20

Ref country code: HU

Payment date: 20231106

Year of fee payment: 20

Ref country code: FR

Payment date: 20231024

Year of fee payment: 20

Ref country code: FI

Payment date: 20231116

Year of fee payment: 20

Ref country code: EE

Payment date: 20231023

Year of fee payment: 20

Ref country code: DE

Payment date: 20231017

Year of fee payment: 20

Ref country code: CZ

Payment date: 20231026

Year of fee payment: 20

Ref country code: CY

Payment date: 20231110

Year of fee payment: 20

Ref country code: CH

Payment date: 20231201

Year of fee payment: 20

Ref country code: BG

Payment date: 20231101

Year of fee payment: 20

Ref country code: AT

Payment date: 20231025

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20231027

Year of fee payment: 20

Ref country code: BE

Payment date: 20231026

Year of fee payment: 20

REG Reference to a national code

Ref country code: SI

Ref legal event code: SP73

Owner name: BAYER INTELLECTUAL PROPERTY GMBH; DE

Effective date: 20240130

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20240105

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 502004006218

Country of ref document: DE

Ref country code: NL

Ref legal event code: MK

Effective date: 20241112

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

Expiry date: 20241113

REG Reference to a national code

Ref country code: LT

Ref legal event code: MM9A

Effective date: 20241113

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20241128

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20241112

Ref country code: SK

Ref legal event code: MK4A

Ref document number: E 3201

Country of ref document: SK

Expiry date: 20241113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20241121

REG Reference to a national code

Ref country code: BE

Ref legal event code: MK

Effective date: 20241113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20241121

REG Reference to a national code

Ref country code: IE

Ref legal event code: MK9A

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 385782

Country of ref document: AT

Kind code of ref document: T

Effective date: 20241113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20241112

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20241113

Ref country code: CZ

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20241113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20241113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20241114

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20241113

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20241113

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20241112

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20241114

Ref country code: CZ

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20241113

REG Reference to a national code

Ref country code: HR

Ref legal event code: PB20

Ref document number: P20080150

Country of ref document: HR

Effective date: 20241113